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Chapter 1. 
 
Arsenic metabolites are bound to proteins in the trivalent form 
 
Abstract 
Inorganic arsenic is converted to methylated metabolites and most is excreted in urine 
as dimethylarsinic acid in humans and animals. The present study was conducted to 
investigate the metabolism of arsenic and identify hepatic and renal metabolites of 
arsenic after an intravenous injection of arsenite (0.5 mg As/kg body weight) in rats. 
Similar levels of arsenic were found in the soluble (SUP) and non-soluble sediment  
(PPT) fractions of both organs after 1 h. More than 80% of the SUP arsenic was bound 
to high molecular weight (HMW) proteins in both organs. Arsenic bound to the HMW 
and PPT proteins were oxidized with H2O2 and released in the pentavalent forms 
(arsenate, monomethylarsonic and dimethylarsinic acids). The relative ratios of the 
three arsenicals changed depending on organ, fraction (HMW and PPT), and time. Since 
the arsenic metabolites/intermediates were liberated from proteins by oxidation with 
H2O2 and recovered in the pentavalent forms, and only tri- but not pentavalent 
arsenicals were bound to proteins in vitro, it was deduced that arsenic metabolites 
bound to proteins during the successive methylation pathway are in the trivalent forms, 
i.e., successive methylation reaction takes place with simultaneous reductive rather than 
stepwise oxidative methylation. Thus, based on the present observations, it was 
proposed that inorganic arsenic was successively methylated reductively in the presence 
of glutathione, rather than a stepwise oxidative methylation, and pentavalent arsenicals 
(MMAV and DMAV) were present as end products of metabolism, rather than 
intermediates. We also discussed the in vitro formation of dimethylthioarsenicals after 
incubating dimethylarsinous acid with liver homogenate. 
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Introduction 
Inorganic arsenic (iAs), which includes arsenate (iAsV) and arsenite (iAsIII), 
can produce both acute and chronic toxicity (1-7). Toxicity is associated with 
metabolites from inorganic arsenic leading to dimethylarsinic acid (DMAV), the major 
urinary metabolite, and/or the related reactions (7-11). Inorganic arsenic is transformed 
to DMAV through consecutive reduction and methylation reactions (12, 13). The 
trivalent forms, rather than the pentavalent forms, are associated with toxicity (14-17); 
however, the precise metabolic pathway and mechanisms for formation of specific toxic 
metabolites are poorly understood. 
Glutathione (GSH)-conjugated forms of trivalent arsenic, iAsIII and 
monomethylarsonous acid (MMAIII), are excreted in bile; however, biliary excretion 
occurs primarily at high doses. The major route of metabolism is conversion to 
dimethylarsinous acid (DMAIII), which is released into the bloodstream. The 
GSH-conjugated forms, arsenotriglutathione [iAsIII(GS)3] and 
monomethylarsenodiglutathione [MMAIII(GS)2], are excreted into the bile through the 
multidrug resistance protein 2 / canalicular multi-specific organic anion transporter 
(MRP2/cMOAT). This process results in enterohepatic circulation, which occurs during 
the metabolism of inorganic arsenicals (18-20). Although iAsIII(GS)3 and MMAIII(GS)2 
were detected in the bile, dimethylarsenoglutathione [DMAIII(GS)] has not been 
detected in the bile (21, 22). In addition, none of the GSH-conjugated forms have been 
detected in the liver (18-23). Nevertheless, the major portion of ingested arsenic is 
released into the bloodstream, mostly in the form of dimethylated arsenicals, which are 
taken up by red blood cells (RBCs), and then finally excreted in urine in the case of rats. 
Preferential accumulation of DMAIII in RBCs was attributed to hemoglobin binding 
(24,25). However, the precise mechanism leading to the formation of the dimethylated 
arsenical (DMA) and the transporter for excretion into the bloodstream have not been 
identified.  
We proposed a procedure for analyzing arsenic metabolites by fractionating 
organs into soluble (SUP) and non-soluble sediment (PPT) fractions, as shown in Figure 
1 (8). The SUP fraction (fraction A in Figure 1) is analyzed by HPLC-inductively 
coupled argon plasma mass spectrometry (ICP MS). Unfortunately, arsenic in the PPT 
fraction cannot be analyzed by HPLC-ICP MS analysis, and arsenic species, such as 
methylated forms and their electronic charges, cannot be characterized when bound to 
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proteins. Therefore, arsenic in the non-soluble PPT and soluble HMW proteins were 
oxidized to the corresponding pentavalent forms, which were liberated from proteins 
because pentavalent forms are not bound to proteins through thiol groups. 
The present study was conducted to identify the arsenic metabolic pathway by 
speciating time-dependent changes in arsenic metabolites recovered in the liver and 
kidneys by focusing on arsenic metabolites bound to HMW and PPT proteins (Figure 1). 
We examined the interaction of arsenicals with soluble and non-soluble proteins in rat 
liver homogenate by incubating various arsenic species (pentavalent iAsV, MMAV and 
DMAV, and trivalent iAsIII, MMAIII and DMAIII).  
 
Materials and Methods 
Reagents.  
All reagents were of analytical grade. Milli-Q water (Millipore) was used throughout. 
Trizma® HCl and Trizma® Base were purchased from Sigma (St. Louis, MO, USA). 
Hydrogen peroxide (30 % v/v), sodium sulfide (Na2S), concentrated sulfuric acid, nitric 
acid, hydrogen chloride, ammonium acetate, acetic acid, 28 % ammonia solution, 
sodium arsenate, sodium arsenite, L-cysteine (Cys), and dimethylarsinic acid 
[(CH3)2AsO(OH)] (DMAV) were purchased from Wako Pure Chemical Industries, Ltd. 
(Osaka, Japan). Monomethylarsonic acid [CH3AsO(OH)2] (MMAV) and arsenobetaine 
(AsB) were purchased from Tri Chemical Laboratories, Inc. (Yamanashi, Japan). The 
arsenic standard solution (1,000 µg/mL) for ICP MS was purchased from SPEX 
CentiPrep (Metuchen, NJ, USA). Stock solutions of all arsenic compounds (10 mM) 
were prepared in purified water, stored in the dark at 4 ˚C, and diluted daily prior to use.  
Preparation of DMAIII and MMAIII from DMAV and MMAV, respectively. 
DMAIII and MMAIII were prepared by reducing DMAV and MMAV, respectively, with 5 
molar equivalents of L-cysteine in distilled water at 70 ˚C for 1.5 h or 90 °C for 1 h. The 
trivalent forms were confirmed by comparison of the respective retention times on a GS 
220 gel filtration column by HPLC-ICP MS with those prepared from their iodide forms 
(26) in distilled water under nitrogen atmosphere. 
Preparation of Dimethylthioarsenicals from DMAV. 
Dimethylmonothioarsinic acid (DMMTAV) was assigned by mistake as 
dimethylthioarsinous acid (DMTAIII) (27), and then revised based on X-ray analysis 
data (unpublished observations). The corrected structure was identical to published 
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structures (28, 29). DMMTAV was prepared by stepwise addition of conc. H2SO4 to an 
aqueous solution of 38 mM DMAV and 60 mM Na2S at the final molar ratio of DMAV : 
Na2S : H2SO4 = 1 : 1.6 : 1.6, and the reaction solution was allowed to stand for 1 h. 
DMMTAV was extracted with ethylether, and then recrytallized from ethylether 
/methanol in an atmosphere of nitrogen. 
Dimethyldithioarsinic acid (DMDTAV) was prepared by stepwise addition of 
conc. H2SO4 to an aqueous solution of 10 mM DMAV and 75 mM Na2S at the final 
molar ratio of DMAV : Na2S : H2SO4 = 1 : 7.5 : 7.5, and the reaction solution was 
allowed to stand for 1 day (27).  
HPLC-ICP MS Analysis. 
The HPLC system consisted of a PU-610 liquid chromatograph solvent delivery pump 
and a DG 660B-2 degasser (GL Sciences Co., Tokyo, Japan). A polymer-based gel 
filtration column (Shodex Asahipak GS-220 HQ, 300 mm x 7.6 mm i.d., Showa Denko, 
Tokyo) with an exclusion limit of 3 kDa, and a silica-based gel filtration column (Shodex 
Asahipak Protein KW-803, 300 mm x 8.0 mm i.d., Showa Denko) with an exclusion 
limit of 170 kDa were used to separate low and high molecular weight constituents, 
respectively. A Shodex Asahipak ES-502N 7C anion exchange column (100 mm x 7.6 
mm i.d., Showa Denko) was used to separate arsenic species in protein-free solutions. A 
20 µL aliquot of a sample solution was applied to a column, and the column was eluted 
with 50 mM ammonium acetate buffer (pH 6.5 at 25 ˚C) or 15 mM citric acid buffer 
(pH 2.0 at 20 ˚C) for a gel filtration GS-220 HQ column or an anion exchange column, 
at the flow rate of 0.6 or 1.0 mL/min. A 200 µL aliquot of a sample solution was applied 
to a Protein KW-803 column, and the column was eluted with 50 mM Tris-HNO3 (pH 
7.4 at 25 ˚C). Arsenic in the eluate was monitored with an HP 4500 ICP MS (Yokogawa 
Analytical Systems, Hachiouji, Japan) at m/z 75. The signal at m/z 77 was also 
monitored to compensate the molecular interference by ArCl+. On-line ICP MS data 
were processed with software developed in house. 
Animal Experiments. 
Male Wistar rats (Clea Japan Co., Tokyo) were purchased at 5 weeks of age and housed 
in a humidity-controlled room maintained at 22-25 ˚C with a 12 h light-dark cycle. Rats 
were given free access to a commercial diet (CE-2; Clea Japan Co.) and tap water. After 
a 1-week acclimation period, rats weighed 160-180 g and were assigned to experimental 
groups. Three rats per group were injected intravenously into a tail vein with arsenite at 
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a single dose of 0.5 mg As/ kg body weight. Controls were injected with an equivalent 
volume of saline vehicle. 
Whole Body Perfusion.  
Since arsenic accumulates preferentially in RBCs of rats in the form of DMAIII, blood 
was removed by whole body perfusion with phosphate-buffered saline (PBS, pH 7.4 at 
25 ˚C) for 10 min at room temperature (23). Afterwards, the livers and kidneys were 
excised and stored at -80 ˚C until use. 
Preparation of Liver and Kidney Supernatants for HPLC-ICP MS Analysis. 
Fresh homogenates (20 %, w/v) of livers and kidneys were prepared in 100 mM 
ammonium acetate solution (pH 6.5 at 25 ˚C, dissolved oxygen was purged by bubbling 
with 99.999 % nitrogen gas) with a glass-Teflon homogenizer in an atmosphere of 
nitrogen, and then centrifuged at 105,000 g for 1 h at 4 ˚C to obtain the supernatant 
fraction (Figure 1, fraction A) and non-soluble sediment fraction (Figure 1, PPT-1). A 
1.0 mL portion of each supernatant was dialyzed with a Slide-A-Lyzer dialysis cassette 
(Pierce, Rockford, Ill, USA) (cutoff molecular weight, MW<10 kDa) in 500 mL of 100 
mM ammonium acetate (pH 7.4) at 4 ˚C for 12 h to give a dialyzed fraction (Figure 1, 
fraction B). The dialysis buffer was changed every 6 h. The dialyzed supernatants 
(Figure 1, fraction B) were heat-treated at 72 ˚C for 30 min, chilled in an ice-bath, and 
centrifuged at 3,000 g for 10 min to obtain the heat-stable soluble (Figure 1, fraction C) 
and heat-denatured protein (precipitate) (Figure 1, PPT-2) fractions. After washing with 
PBS three times, the heat-denatured proteins (precipitate) were oxidized with 0.5 mL of 
30 % H2O2 at room temperature for 3 h to give an oxidized fraction (Figure 1, fraction 
D). The non-soluble sediment fractions of rat liver and kidney homogenates (Figure 1, 
PPT-1) were washed with PBS three times, heat-treated to deactivate catalase activity, 
and then oxidized with 0.5 mL of 30 % H2O2 at room temperature for 3 h to give an 
oxidized fraction (Figure 1, fraction E). Arsenic metabolites in the non-soluble (Figure 1, 
PPT-1 and –2) and soluble HMW proteins (Figure 1, B) were determined as the 
corresponding oxidized arsenicals (iAsV, MMAV and DMAV) on an anion exchange 
column. 
in vitro Incubation System.  
To assay the affinity and reaction of arsenic compounds with liver constituents and to 
compare those with the arsenic distributions detected in vivo, pentavalent (iAsV, MMAV 
and DMAV) and trivalent (iAsIII, MMAIII and DMAIII) arsenicals were incubated in a 
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20 % (w/v) fresh rat liver homogenate (in 100 mM ammonium acetate solution, pH 7.0 
at 25 ˚C) at the final concentrations of 0.1, 0.5 and 1.0 µg/mL at 37 °C for 30 min. The 
incubation mixture was centrifuged at 105,000 g at 4 ˚C for 1 h to give the supernatant 
(SUP) and sediment (PPT) fractions. Arsenic in the SUP fraction was subjected to 
HPLC-ICP MS analysis on two gel filtration columns (polymer-based GS-220 HQ and 
silica-based gel Protein KW-803 gel filtration columns for arsenicals of LMW constituents and 
those bound to HMW proteins, respectively.  
Determination of Arsenic Concentrations with ICP MS. 
Concentrations of arsenic in liver and kidney homogenates and in SUP and HMW 
proteins fractions were determined with an ICP MS (HP 4500) after wet-ashing with a 
mixed acid of concentrated nitric acid (HNO3) and 30 % H2O2 (v/v=1/1).  
 
Results 
Trivalent arsenicals are readily oxidized and recovered quantitatively as 
pentavalent arsenicals, such as iAsV, MMAV and DMAV. Likewise, arsenic bound to 
proteins can be readily liberated by oxidation with H2O2 and recovered quantitatively as 
free pentavalent arsenicals. Therefore, arsenic in non-soluble and soluble HMW 
proteins was oxidized with H2O2 to liberate them as soluble pentavalent forms before 
HPLC-ICP MS analysis (Figure 1). Since H2O2 is decomposed by catalase, catalase was 
deactivated by heat-treatment. 
We selected a gel filtration GS 220 HQ column for LMW arsenicals because 
most arsenicals were separated on this column, as demonstrated in Figure 2A). Because 
arsenate (iAsV) and MMAV eluted with identical retention times, they were separated on 
an anion exchange column (Figure 2B).  
Hepatic and renal arsenic metabolites were separated into five fractions (A-E) 
as outlined in Figure 1, and arsenic species were determined using gel filtration (panels 
A and B in Figures 3 and 4) and/or anion exchange (panels C, D and E in Figures 3 and 
4) columns. Figures 3A and 4A show that arsenic metabolites in the cytosolic fraction 
(fraction A in Figure 1) were mostly bound to HMW proteins (void volume) in both 
livers and kidneys, and minor LMW metabolites were assigned as iAsV/MMAV, DMAV 
and AsB. An arsenic peak corresponding to dimethylthioarsenicals (DMTA) was barely 
detected.  
The minor metabolites in the soluble fraction in Figures 3A and 4A were 
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removed by dialysis (Figures 3B and 4B). The arsenic species bound to HMW proteins 
were heat-treated to give heat-stable soluble (fraction C in Figure 1) and heat-denatured 
precipitate fractions (PPT-2), the latter fraction was oxidized to give fraction D in 
Figure 1 and recovered as the corresponding pentavalent arsenicals. Although the 
heat-treatment process was intended only to deactivate catalase, arsenic metabolites in 
fraction B (panel B in Figures 3 and 4) were separated into tightly and loosely bound 
arsenic metabolites by this heat-treatment (fractions C and D in Figure 1, respectively).  
Arsenic in fraction C (Figures 3C and 4C) gave different distributions in the 
liver and kidneys. DMAV was the major arsenic in the liver, and iAsIII and iAsV were 
major metabolites in the kidneys. Since DMAV and iAsV were not present in fraction B 
(Figures 3B and 4B), we assumed that HMW proteins were oxidized during the dialysis 
process, and DMAIII and iAsIII bound to oxidized HMW proteins were liberated and 
oxidized in parts during the heat-treatment process, and then recovered in fraction C as 
their pentavalent forms. Namely, arsenic-binding proteins might be oxidized in the 
absence of GSH during dialysis, and the oxidized proteins induced oxidation of 
arsenicals bound to the proteins. iAsIII detected in the heat-stable soluble fraction in the 
kidneys (Figure 4C) seems to be present in forms bound to proteins loosely and 
liberated from denatured proteins. 
Arsenic in fraction D (Figures 3D and 4D) also gave different arsenic 
distributions between the two organs; Levels of iAsV and MMAV were greater in the 
kidneys. These observations suggested that arsenic metabolites in the soluble fraction of 
liver and kidneys were present in the trivalent forms bound to HMW proteins, and these 
species changed with time depending on organs and time. It also indicated that 
methylation of arsenic took place more efficiently in the liver than in the kidneys, and 
that MMAIII was bound to proteins with greater affinity and tenacity than iAsIII and 
DMAIII.  
The sediment (PPT-1) fraction was first heated to deactivate catalase, and then 
oxidized with H2O2 to give fraction E (Figure 1). Arsenic species in fraction E (Figures 
3E and 4E) indicated that arsenic in the non-soluble sediment (PPT-1) fraction was 
present as the three trivalent arsenicals (iAsIII, MMAIII and DMAIII), and their relative 
ratios and concentrations changed over time, depending on the organ. Namely, arsenic 
in the PPT-1 fraction was present more in the iAsIII and MMAIII forms in the kidneys 
than in the livers (Figures 4E and 3E, respectively). These observations suggested that 
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arsenite was bound to non-soluble PTT proteins and mono-methylated (first 
methylation) in the PPT-1 fraction and then further methylated (second methylation) in 
the soluble HMW fraction or DMAIII was more readily bound to soluble proteins. 
 Concentrations of arsenic in homogenates, supernatant (fraction A) and HMW 
protein fraction (fraction B) were determined to assess the relative distributions of 
arsenic in the liver and kidneys, as shown in Figure 5. Arsenic was present in forms 
bound to non-soluble PPT proteins (50 %) and soluble HMW proteins (40 %). Arsenic 
recovered as soluble LMW arsenicals, such as arsenate, DMAV and DMDTAV, was less 
than 15 %. 
 The difference in the distribution of arsenic between tri- and pentavalent 
arsenicals was investigated in vitro by incubating the tri- and pentavalent arsenicals in a 
20% liver homogenate (Figures 6 and 7). Although the minor arsenic peak at the void 
volume was detected at all doses of the three arsenicals, the three pentavalent arsenicals 
were recovered quantitatively in their original forms (Figure 6). A small but exceptional 
peak was detected at the retention time corresponding to DMDTAV after incubation 
with DMAV (Figure 6C). This is probably because DMAV was reduced to DMAIII, and 
then reacted with sulfane sulfur to produce DMDTAV (sulfuration), as observed by 
incubation with DMAIII in Figure 7.  
In contrast to the pentavalent arsenicals, trivalent arsenicals bound to various 
proteins (Figure 7). Distributions of arsenic in the soluble fraction were determined on 
two gel filtration columns by HPLC-ICP MS after incubating trivalent arsenicals in a 
20 % homogenate. One column was a GS-220 column for separating LMW arsenicals 
(Figure 7A-C), and the other was a Protein KW-803 column for separating HMW 
proteins (Figure 7D-E). Arsenic derived from iAsIII was recovered mostly with HMW 
proteins (void volume) at the lowest dose, and the relative distribution to iAsIII (intact 
form) increased with dose (Figure 7A). After incubation with MMAIII, arsenic was also 
recovered mostly in the void volume (Figure 7B). However, compared with iAsIII, the 
original arsenical MMAIII (intact form) was not detected and the arsenic was bound to 
HMW proteins together with several unidentified small peaks (Figure 7B), which 
suggested that MMAIII has a higher affinity for HMW proteins than iAsIII. In contrast to 
arsenic derived from iAsIII and MMAIII, arsenic derived from DMAIII produced distinct 
peaks that corresponded to the two dimethylthioarsenicals (DMMTAV and DMDTAV) 
in Figure 7C. Thus, arsenic of DMAIII origin was recovered mostly in the soluble 
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fraction, as shown in Figure 8, and only a small percentage was present in the form 
bound to proteins (Figure 7C).  
The trivalent arsenicals bound to HMW proteins were separated on a Protein 
KW 803 column (Figure 7D-F). Each of the three trivalent arsenicals bound to HMW 
proteins was separated into three peaks (a-c), the main peak c being the smallest 
molecular size. These distributions were similar to those obtained from in vivo 
experiments (data not shown). However, we did not attempt to identify these proteins in 
the present study. 
      Figure 8 shows the quantitative distributions of arsenic in the liver homogenate 
after incubation with penta- and trivalent arsenicals. Although the three pentavalent 
arsenicals were recovered as their original arsenicals in the soluble LMW fraction, the 
trivalent arsenicals, iAsIII and MMAIII, were recovered mostly in the non-soluble 
sediment (PPT) fraction with a similar distribution to that of in vivo observation after 
injection of iAsIII.  In other words, approximately 90 % of the dose was recovered in 
the non-soluble PPT fraction and soluble HMW proteins. A different distribution was 
observed after incubating DMAIII in a liver homogenate. This was similar to the 
distribution profiles on the two gel filtration columns in Figures 7C and D since arsenic 
was recovered in the soluble fraction in the form of two thioarsenicals, DMMTAV and 
DMDTAV after incubation of DMAIII in a liver homogenate.  
 
Discussion 
Metabolites of inorganic arsenicals are either trivalent or pentavalent. Trivalent 
arsenicals are more reactive and readily bind to thiol groups found on proteins and GSH 
(8, 23, 30-32). As a result, they inhibit enzymes, such as glutathione reductase, 
glutathione peroxidases, thioredoxin peroxidase and thioredoxin reductase (33-37). In 
the present study, arsenic metabolites were fractionated (Figure 1) by focusing on 
metabolites bound to soluble HMW and non-soluble sediment (PPT) proteins. The 
authentic standards required for our analysis were separated on two columns and most 
arsenic peaks were identified. Although arsenic species bound to soluble HMW and 
non-soluble PPT proteins were identified in their oxidized forms (iAsV, MMAV and/or 
DMAV), their proteins were characterized only on a gel filtration column and no further 
analysis was conducted.  
The present study showed that arsenic found in the liver and kidneys was 
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detected mostly in the forms bound to soluble and non-soluble proteins. Free 
pentavalent arsenicals were present only as minor metabolites in both organs. Since 
trivalent but not pentavalent arsenicals were bound to proteins (Figures 6 and 7), and 
protein-bound arsenicals were recovered quantitatively as pentavalent arsenicals by 
oxidation with hydrogen peroxide (Figures 3 and 4) as in the case of oxidation of 
trivalent arsenicals, protein-bound arsenicals in the soluble and non-soluble proteins 
observed in the present study were deduced to be in the trivalent forms. Although this 
assumption can be supported by the observation that trivalent arsenicals bound to 
hemoglobin were trivalent forms by mass spectral data (25), definitive evidences may 
be required for arsenicals bound to general proteins.     
The relative ratios among the three arsenic metabolites (iAs, MMA and DMA) 
were variable depending on organs, soluble/non-soluble proteins, and time after the 
administration. Although some tendencies were observed such as a tendency to decrease 
with time after distribution in both organs for iAs in the sediment fraction (Figures 3E 
and 4E), overall tendency to demonstrate the metabolism from iAs to MMAIII and then 
to DMAIII with time was not obtained in the present chromatograms in Figures 3 and 4. 
This is probably because of the presence of complex arsenic metabolites in each fraction 
reflecting the capacity of transformation reactions such as the first and second 
methylation reactions in different organs and subcellular fractions. However, several 
observations suggested that the metabolic transformation of arsenic takes place more 
efficiently in the liver than in the kidneys. Namely, although MMA was detected only at 
an early time point in the liver, it was detected at all time points with increasing over 
time in the kidneys.  
Methylation reaction of arsenicals requires a methyl donor (SAM) and a 
reductant (GSH), and methylation occurs either oxidatively (oxidative methylation 
followed by reduction) or reductively (simultaneous methylation and reduction, i.e., 
reductive methylation). The reaction mechanisms for the two methylation reactions can 
be schematically presented, as shown in Figure 9. The oxidative methylation is initiated 
by the nucleophilic attack of unshared electron pair of arsenic atom to methyl cation 
followed by the oxidation of arsenic atom. The following reduction of the methylated 
arsenical takes place independently from the oxidative methylation. On the other hand, 
the reductive methylation is initiated by the transfer of unshared electron pair of arsenic 
atom to methyl cation with simultaneous reduction of the arsenic atom by conjugated 
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GSH. As(R)n(SG)m conjugates can not form pentavalent species as intermediates during 
methylation reactions because of reductive ability of GSH, but does form methylated 
trivalent species directly. Conjugated GSH, then, reacts with bulky GSH to form GSSG. 
Another ligand (shown in the scheme as –R) could be –SG or proteinous thiolate of 
cysteine residue, but proteinous cysteine is more preferable because of its affinity to 
trivalent arsenic species (25). Thus, the presence of arsenic metabolites in the forms 
bound to proteins suggests that the methylation takes place reductively. Although the 
enzymes for each reduction and methylation reaction were identified by Aposhian’s 
group (12, 38-40), and MMAV was incorporated and transformed to DMA in rats (23), 
Hayakawa et al. (41) demonstrated that MMAIII(SG)2 was methylated, but free MMAIII 
was not methylated by Cyt 19 (AS3MT). As trivalent arsenicals are not methylated in 
the absence of a reductant, the oxidative methylation does not occur in the methylation 
mechanism in Figure 9. Thus, it is reasonably deduced from the following observations 
that arsenic is reductively methylated consecutively in the forms bound to proteins. 
Namely, arsenic metabolites were found in the forms bound to proteins in the present 
study, and methylation of trivalent arsenicals by Cyt 19 (AS3MT) cannot take place in 
the absence of GSH (41). 
Dimethylthioarsenicals (DMTA) can be detected in the liver of rats given 
DMAV and MMAV (23). DMTA can be prepared chemically by reacting DMAV with 
hydrogen sulfide or by incubating it in a reaction medium that generates hydrogen 
sulfide, such an acidified sodium sulfide solution (27). From the chemical and 
biological properties, we identified two DMTA metabolites as dimethylthioarsinous 
acid (DMTAIII) and dimethyldithioarsinic acid (DMDTAV) (27). However, after precise 
re-examinations of the two DMTA, including X-ray crystallographic determination, we 
agreed with published structures (28, 29). Since DMTA can be prepared only with 
trivalent DMA (DMAIII or a DMAIII-generating system) and a sulfide source, DMTAIII 
was assumed to be the direct reaction product of DMAIII and sulfide. However, 
DMTAIII was never detected and the reaction products were pentavalent monothiolated 
(DMMTAV) and dithiolated (DMDTAV) arsenicals. Their relative ratio changed 
depending on the reaction conditions, and DMMTAV was transformed to DMDTAV in 
the presence of sufficient sulfide.  
The most significant difference between in vivo and in vitro experiments was 
the subcellular distribution of dimethylated arsenicals. Dimethylated arsenicals of 
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arsenite origin (in vivo) were bound mostly to the non-soluble PPT and soluble HMW 
proteins (Figures 3 and 4). In contrast, DMAIII incubated in the liver homogenate (in 
vitro) was recovered mostly from the soluble fraction in the form of thioarsenicals 
(DMMTAV and DMDTAV) (Figure 7). This difference may be explained as follows: 
DMTA can be produced in the presence of trivalent (but not pentavalent) 
dimethylarsenical (DMAIII) and sulfane sulfur. DMAIII can be produced metabolically 
after an injection of iAsIII and found as free DMAIII, GSH-conjugated DMAIII 
(DMAIII(GS)) and/or protein-bound DMAIII (protein-S-DMAIII) (in the order of 
decreasing reactivity). On the other hand, sulfane sulfur may be present in the form of 
free HS-, proteinous R-S-SH and/or trisulfide R-S-S-S-R (in the order of decreasing 
reactivity), the three forms being convertible depending on the availability of GSH. As 
observed in the present experiments (Figures 3 and 4), DMAIII of iAsIII origin was 
present mostly in the protein-bound forms and reacted poorly with any forms of sulfane 
sulfur. However, when DMAIII was supplied in the form of reactive free DMAIII, as in 
the case of the present in vitro experiment (Figure 7), it seems to react with all forms of 
sulfane sulfur to produce DMTA. Thus, as free DMAIII was incubated in a liver 
homogenate in vitro, it reacted readily with sulfane sulfur, resulting in the production of 
DMTA (DMMTAV and DMDTAV) (Figure 7). On the other hand, in in vivo experiment, 
dimethylated arsenical was produced in situ on the protein-bound arsenic to form 
protein-S-As(CH3)2 from iAsIII and bound to soluble and non-soluble proteins, which 
made arsenic less reactive and arsenic remained without reacting with sulfane sulfur (in 
the form bound to soluble and non-soluble proteins).  
Although we did not study further in the present experiments, the three 
arsenic-binding proteins (a, b and c in Figures 7D, E and F) seem to be similar to or 
identical with those reported by several groups; Vahter and Marafante (30) reported 
three arsenic-binding proteins in the mice and rabbit liver and kidney cytosols in vivo 
and in vitro on a Sephacryl S-200 column. Aposhian’s group (31) also detected three 
arsenic-binding proteins of >2,000, 450 and 100 KDa on a Sepharose 4B-CL column 
from rabbit liver cytosols. Styblo and Thomas (32) detected three arsenic-binding 
proteins of >1,000, 135 and 38 KDa on a Sephacryl S-300 column from rat liver 
cytosols. Although gel filtration columns used in the three research groups were 
different each other and also from the present column, these three arsenic-binding 
proteins seem to be similar or identical.  
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Based on the present observations and proposed schemes, arsenic administered 
in the form of arsenite was explained to be metabolized as the schematically drawn in 
Figure 10. Namely, arsenite taken up by organs (liver) is conjugated with soluble and 
non-soluble proteins, and then methylated reductively in the presence of SAM by the 
conjugation of -SH groups (GSH and/or –SH groups of cysteinyl residues on proteins 
(reductive methylation) to produce mono- (first methylation) and dimethylated 
arsenicals (second methylation). This reductive methylation mechanism seems to 
explain the mechanism proposed by Hayakawa et al. (41) and Aposhian and Aposhian 
(42). The second methylation reaction seems to be the limiting rate and excessive doses 
may produce iAsIII(GS)3 and MMAIII(SG)2, and induce their excretion into bile (9, 
18-20). iAsV and MMAV may not be present as intermediates but as end products of 
metabolism. When DMAIII is liberated from proteins in the forms of free DMAIII and/or 
DMAIII(SG), they seem to be reacted with sulfane sulfur producing 
dimethylthioarsenicals (DMMTAV and DMDTAV). DMAIII bound to proteins is 
assumed to be excreted into the bloodstream as the major route for the excretion of 
arsenic from the liver by the participation of an unknown nucleophile (X-). However, 
the precise identity of X in this excretion form (CH3)2AsX) remained to be clarified. 
Nevertheless, before being excreted from the liver or other organs, the present study 
showed that arsenic is bound to proteins in the form of DMAIII as the stable and less 
reactive form.
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Figure 1. Procedures for the preparation of organ samples and speciation of 
arsenic. Arsenite was injected intravenously into rats at a dose of 0.5 mg As/kg body 
weight.  Livers and kidneys were removed 5, 10, 30 and 60 min later and homogenized 
in four volumes of the extraction buffer to obtain the supernatant (SUP) (A) and 
sediment fractions (PPT-1). The supernatant (A) was dialyzed to remove low molecular 
weight (LMW) constituents (MW<10,000). The dialyzed supernatant (arsenic bound to 
high molecular weight (HMW) proteins) (B) was heat-treated at 72 ˚C for 30 min to 
denature proteins and to deactivate catalase, chilled in an ice-water, and then 
centrifuged to obtain the heat-stable soluble (C) and heat-denatured fractions (PPT-2). 
The heat-denatured fraction (PPT-2) was oxidized with H2O2 to give the 
heat-denatured/precipitated/oxidized fraction (D). The sediment (PPT-1) fraction of the 
homogenate was heat-treated to deactivate catalase and then oxidized with H2O2 to give 
the precipitated/heated/oxidized (E) fraction. The five fractions were subjected to 
speciation analysis by HPLC-ICP MS on a gel filtration GS 220 column (A and B 
fractions) and on an anion exchange ES 502N 7C column (C, D and E fractions). The 
distribution profiles of arsenic were depicted for the liver (Figure 3) and kidney 
fractions (Figure 4).  
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Figure 2. HPLC-ICP MS profiles of authentic arsenicals on gel filtration GS-220 
HQ (A) and anion exchange ES-502 7N (B) columns. 
A 20 µL solution of authentic arsenite (iAsIII), arsenate (iAsV), monomethylarsonic acid 
(MMAV), dimethylarsinic acid (DMAV), arsenobetaine (AsB), dimethylmonothioarsinic 
acid (DMMTAV) and dimethyldithioarsinic acid (DMDTAV) (0.1 µg/mL each) were 
subjected to HPLC-ICP MS analysis on gel filtration GS 220 (A) and anion exchange 
ES-502 columns (B) by elution with 50 mM ammonium acetate buffer (pH 6.5 at 25 ˚C) 
and 15 mM citric acid buffer (pH 2.0 at 20 ˚C) at the flow rate of 0.6 and 1.0 ml/min, 
respectively. Mixtures of the following authentic samples were eluted for each 
chromatogram; A-i) MMAV + DMAV + DMDTAV + DMMTAV; A-ii) AsB ; A-iii) iAsV 
+ iAsIII; B-i) DMAV + MMAV + iAsV; B-ii) iAsIII; B-iii) DMDTAV + DMMTAV. 
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Figure 3. Changes in the distributions of arsenic on gel filtration and anion 
exchange columns by HPLC-ICP MS in various liver fractions with time after an 
intravenous injection of arsenite. 
The livers were excised and processed according to the procedure described in the 
legend to Figure 1, and subjected to HPLC-ICP MS analysis; fractions A and B, and C-E 
in Figure 1 on a gel filtration GS 220 column to separate arsenic metabolites into high 
(HMW) and low molecular weight (LMW) arsenic, and on an anion exchange column 
to further separate LMW arsenic, respectively. Panels A-E correspond to the fractions 
A-E in Figure 1, respectively. The vertical bar shows the detection level for arsenic.  
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Figure 4. Changes in the distributions of arsenic on gel filtration and anion 
exchange columns by HPLC-ICP MS in various kidney fractions with time after an 
intravenous injection of arsenite. 
The kidneys excised and processed according to the procedure described in the legend 
to Figure 1 were subjected to HPLC-ICP MS analysis in the same manner as of the 
livers in Figure 3. 
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Figure 5. Time-related changes in the distribution ratios of arsenic in the liver and 
kidneys after an intravenous injection of arsenite. 
The liver and kidney homogenates (Hom) prepared from the rats (n=3) injected with 
arsenite were fractionated into the supernatant (SUP) and precipitate (PPT) fractions as 
described in the legend to Figure 1. Arsenic in the supernatant (SUP) was processed 
further to give the high molecular weight (HMW) fraction by dialysis with a dialysis 
cassette in 50mM ammonium acid buffer, pH 7.4 (500 mL) at 4 ˚C for 12 h, the dialysis 
buffer being changed every 6 h. Arsenic concentrations in the Hom, SUP and HMW 
were determined after acid digestion with HNO3/H2O2, while those in the PPT and 
LMW were calculated (Hom – SUP and SUP – HMW, respectively). Thus, arsenic in 
the Hom was fractionated into the supernatant (Sup-HMW (graduated square) and 
Sup-LMW (closed square)) and PPT (open square) fractions, and expressed as 
percentile distributions. The arsenic concentration in the Hom (square symbol) was 
expressed as mean±S.D. (n=3). 
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Figure 6. Arsenic distributions in the liver supernatant after incubation in vitro of 
pentavalent arsenicals in a liver homogenate on a gel filtration column by 
HPLC-ICP MS. 
The pentavalent arsenicals, iAsV (A), MMAV (B) and DMAV (C) were incubated in 
vitro in a 20 % liver homogenate at a final concentration of 0.1, 0.5 or 1.0 µg As/mL at 
37 ˚C for 30 min, and then the homogenate was centrifuged at 105,000 g for 1 h to give 
the supernatant. A 20 µL portion of the liver supernatant was subjected to HPLC-ICP 
MS analysis on a gel filtration GS 220 column. The vertical bar shows the detection 
level of arsenic. 
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Figure 7. Arsenic distributions in the liver supernatant after incubation in vitro of 
trivalent arsenicals in a liver homogenate on two gel filtration columns by HPLC-ICP 
MS. The trivalent arsenicals, iAsIII (A and D), MMAIII (B and E) and DMAIII (C and F) 
were incubated in vitro in a 20 % liver homogenate at a final concentration of 0.1, 0.5 or 
1.0 µg As/mL at 37 ˚C for 30 min, and then the homogenate was centrifuged at 105,000 
g for 1 h to obtain the supernatant. A 20 (A-C) or 200 µL (D-F) portion of the 
supernatant was subjected to HPLC-ICP MS analysis on gel filtration GS 220 (A-C) and 
Protein KW-803 (D-F) columns to separate LMW arsenicals (A-C) and arsenicals 
bound to HMW proteins (D-F), respectively. Panels A, B, C and F were drawn with two 
detection levels. 
Retention time (min) 
DMDTAV 
DMAV 
AsB 
DMMTAV 
30 20 15 10 5 30 20 15 10 5 30 20 15 10 5 25 25 25 
30 20 15 10 5 30 20 15 10 5 30 20 15 10 5 25 25 25 
iAsV 
iAsIII 
AsB AsB 
unknown 
AsB AsB 
iAsIII a a 
b c b c c 
DMAV 
0.1 µg/mL 
0.5 µg/mL 
1.0 µg/mL 
0.5 µg/mL 
1.0 µg/mL 
iAsV 
(A) (B) (C) 
(D) (E) (F) 
void-  
volume-  
DMMTAV 
DMDTAV 
void-  
volume-  
void-  
volume-  
a b 
2.0 µM 2.5 µM 5.5 µM 
unknown 
320 nM 430 nM 150 nM 
0.1 µg/mL 
 29 
 
 
 
 
 
 
 
 
Figure 8. Distribution ratios of arsenic in the liver homogenate after incubation in 
vitro with penta- and trivalent arsenicals. 
Penta- and trivalent arsenicals (iAs, MMA and DMA) were incubated in a 20 % liver 
homogenate at a final concentrations of 0.1, 0.5 or 1.0 µg As/mL, and then the arsenic 
was fractionated to the supernatant (SUP) and precipitate (PPT (open square)) fractions. 
Arsenic in the SUP was further fractionated to Sup-HMW (graduated square) and 
Sup-LMW (closed square) fractions. Arsenic in the three fractions was expressed as 
mean percentile distributions.  
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Figure 9. Reaction mechanisms for oxidative and reductive methylation. 
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Figure 10. Proposed metabolic pathway for arsenic 
Arsenite taken up by the liver is bound to non-soluble and soluble proteins through thiol 
groups on a protein or GSH. Methylation takes place on arsenic bound to proteins in the 
presence of S-adenosylmethionine (SAM) and glutathione (GSH). In other words, 
methylation and reduction take place simultaneously in the presence of SAM and GSH, 
not separately with oxidative methylation followed by reduction. Arsenic bound to 
proteins can be liberated from proteins by conjugation with GSH to form iAs(SG)3 and 
CH3As(SG)2. However, the major route for arsenic metabolism takes place 
consecutively by reductive methylation to produce (CH3)2As-protein, and dimethylated 
arsenic is liberated by the attack of a nucleophile (X-) to produce (CH3)2AsX. One of 
(CH3)2AsX may be the form for excretion into bloodstream. On the other hand, sulfide 
(sulfane sulfur) can be a nucleophile to produce trivalent dimethylthioarsenical (DMTA) 
[(CH3)2AsSH], and then it is transformed to pentavalent dimethylthioarsenicals 
(DMMTAV and DMDTAV) [(CH3)2As(S)OH and (CH3)2As(S)SH, respectively].     
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Chapter 2.  
 
Arsenic Metabolism and Thioarsenicals in Hamsters and Rats 
 
Abstract 
The tissue distribution and chemical forms of arsenic were compared in two animal 
species with different metabolic capacity and toxicity to arsenic. Hamsters and rats were 
given a single oral dose of arsenite (iAsIII) at 5.0 mg As/kg body weight, and then the 
concentrations of arsenic were determined; more than 75 % of the dose accumulated in 
rat red blood cells (RBCs) in the form of dimethylarsinous acid (DMAIII), whereas less 
than 0.8% of the dose accumulated in hamster RBCs, mostly in the form of 
monomethylarsonous acid (MMAIII). Reflecting the low accumulation in RBCs, more 
than 63 % of the dose was recovered in hamster urine within one week (7.8-fold higher 
than in rat urine). The quantity of arsenic distributed in the liver and kidneys was 
significantly higher in hamsters than in rats, and arsenic in livers stayed much longer in 
hamsters than in rats. Arsenic accumulated more and was retained longer in kidneys 
than in livers in both animals, and in hamster kidneys it accumulated at higher levels 
than in rat kidneys in the form of MMAIII bound to proteins. In the first 24 hr-urine, 
dimethylmonothioarsinic (DMMTAV) and dimethyldithioarsinic (DMDTAV) acids were 
detected in hamsters, but only DMMTAV was found in rats, together with an unknown 
arsenic metabolite in both animals. The unknown urinary arsenic metabolite was 
identified as monomethylmonothioarsonic acid (MMMTAV; CH3As(=S)(OH)2). The 
present results indicate that in hamsters arsenic does not accumulate in RBCs, and 
therefore hamsters exhibit a more uniform tissue distribution and faster urinary 
excretion of arsenic than rats. In addition, arsenic was thiolated more in hamsters than in 
rats excreting mono- and dimethylated thioarsenicals in urine. 
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Introduction 
Arsenic is one of the most important pollutants of concern occurring in the 
environment, and human health risks such as hyperkeratosis, pigmentation and 
blackfoot disease (1, 2), and lung, skin and urinary bladder cancers (3-5) are increasing 
in populations affected by arsenic-contaminated drinking water. However, the 
mechanisms underlying arsenic-induced diseases and cancers are not precisely 
understood (6). Mammal species are known to respond differently in sensitivity to 
inorganic arsenic (5, 7, 8), hamsters being more susceptible to inorganic arsenic than 
rats (9). In fact, our preliminary study on the metabolism of arsenic showed a distinct 
difference in the metabolism between rats and hamsters, i.e., the most distinct difference 
being the accumulation in red blood cells (RBCs). This species-difference might be 
related to the relevant metabolizing enzymes such as arsenic methyltransferases (10, 11). 
Recently, arsenic methyltransferase (AS3MT) has been identified as a methyltransferase 
for the methylation of arsenic (12) in various animals such as rats, hamsters and rabbits, 
and it is now known to catalyze the multiple steps that convert arsenic to methylated 
metabolites (13). On the other hand, chimpanzees and guinea pigs lack this AS3MT, 
and thus their capacity to methylate arsenic is significantly low (14, 15). Thus, 
methylation capacity may be related to the susceptibility to arsenicals among those 
animal species.  
Trivalent methylated arsenicals monomethylarsonous (MMAIII) and 
dimethylarsinous (DMAIII) acids are more toxic than trivalent inorganic arsenical 
arsenite (iAsIII) in vivo (16), and these trivalent arsenicals are more genotoxic and 
cytotoxic than pentavalent arsenate (iAsV), monomethylarsonic (MMAV) and 
dimethylarsinic (DMAV) acids in vitro (17-20). At the same time, trivalent methylated 
arsenicals are more efficiently taken up than pentavalent methylated arsenicals by 
microvessel endothelial cells and CHO cells (21, 22). Our previous studies showed that 
inorganic arsenicals were primarily taken up by the liver, and transformed to 
monomethylated (MMA) and dimethylated arsenicals (DMA) through consecutive 
reductive methylation, in forms bound to proteins (23), and then finally excreted in 
urine mostly in the form of DMAV in mammals (24-26). It has been reported that 
methylation is an important detoxifying reaction by facilitating excretion of arsenic in 
urine in pentavalent forms (27-29). However, trivalent methylated arsenicals MMAIII 
and DMAIII have been detected in human and animal urine (30-33), in especially 
massive amounts in the forms of DMAIII and MMAIII in the urine of a population 
exposed chronically to inorganic arsenic in Mexico (34). On the other hand, Kala et al. 
reported that iAsIII and MMAIII were excreted in urine in forms conjugated with GSH in 
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g-glutamyl transpeptidase-deficient mice (35). However, as for the metabolite DMAIII in 
urine, Hansen et al. suggested that DMAIII in urine can be mistaken for a 
sulfur-containing arsenical such as dimethylmonothioarsinic acid (DMMTAV) (36). 
We reported that MMAIII and DMAIII were detected in human urine samples 
from arsenic-affected districts of West Bengal, India (31). However, further study 
indicated that the peak assigned as DMAIII was mistaken as a dimethythioarsenical such 
as DMMTAV (37, 38). In addition, we also raised the question as to the identification of 
MMAIII in urine. MMAIII used to be prepared through reduction of MMAV according to 
the Reay and Asher method (39). However, we found that the retention time of the 
product was different from that of standard MMAIII of monomethylarsenyl diiodide 
(MMAI2) origin, and also from that of MMAIII produced from MMAV through 
reduction with L-cysteine on anion exchange and gel filtration columns in accordance 
with the suggestions raised by Feldmann’s group (36, 40). They indicated that an 
unknown arsenical in nail extracts was consistent with one of the reaction products 
derived from MMAV with the Reay and Asher method. These observations can be 
explained by that the reduction of MMAV with the Reay and Asher method produces 
mostly thioarsenicals, and one of them may be identical with one of the urinary arsenic 
metabolites, as in the case of the reduction products of DMAV. 
We have been interested in correlating the chemical species and/or chemical 
reactions occurring in the metabolism of arsenic with the toxicity of arsenic. The present 
study was carried out to gain an insight into the precise metabolic difference between 
two animal species that differ in metabolic capacity and toxicity to arsenic, i.e., 
hamsters and rats (9, 15, 41). In addition to clarifying the differences in the distributions 
among organs/tissues and the differences in arsenic metabolites between the two animal 
species, we focused on thioarsenicals by examining any difference in their presence 
between the two animals. We show that there are distinct difference between the two 
animals in the distributions of arsenic and arsenic metabolites, including thioarsenicals 
DMMTAV and DMDTAV, among organs. Furthermore, an unknown arsenic metabolite 
found in the urine of both animals was identified as monomethylmonothioarsonic acid 
(MMMTAV). 
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Materials and Methods 
Chemicals and Reagents. Sodium arsenite (iAsIII), sodium arsenate (iAsV), 
dimethylarsinic acid (DMAV), hydrogen peroxide (H2O2), nitric acid, hydrogen chloride, 
sodium sulfide (Na2S), sodium thiosulfate, ammonium acetate, deuterium oxide (D2O), 
sulfuric acid-d2 (D2SO4), and Wako gel® 100 C18 (particle size, 63~212 µm) were 
purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), and 
monomethylarsonic acid (MMAV) and arsenobetaine (AsB) from Tri Chemical 
Laboratories, Inc. (Yamanashi, Japan). Trizma HCl and Trizma Base were purchased 
from Sigma (St. Louis, MO, USA). The arsenic standard solution (1000 µg/mL) for 
inductively coupled argon plasma mass spectrometry (ICP-MS) was purchased from 
SPEX Centi-Prep (Metuchen, NJ, USA). Stock solutions of all arsenicals (10 mmol/L) 
were prepared from the respective standard compounds, and stored in the dark at 4 ºC. 
Diluted standard solutions for analysis were prepared daily before use. 
Animal Experiments. All animal experiments were carried out according to the 
"Principles of Laboratory Animal Care" (NIH version, revised 1996) and the Guidelines 
of the Animal Investigation Committee, Graduate School of Pharmaceutical Sciences, 
Chiba University, Japan. 
Male Syrian hamsters (SLC Japan Co., Hamamatsu, Japan) and Wistar rats 
(Clea Japan Co., Tokyo, Japan) were purchased at 7 weeks of age. They were housed in 
a humidity-controlled room, maintained at 22-25 ºC with a 12 hr light-dark cycle. The 
animals were fed a commercial diet (CE-2; Clea Japan Co.) and tap water ad libitum. 
Following a one-week acclimation period, hamsters and rats, at 8 weeks of age, and 
weighing 100-125 g and 180-200 g, respectively, were used for experiments. As 
thioarsenicals were suggested to be produced more in hamsters than in rats in our 
preliminary experiments, and arsenic is known to be distributed more in RBCs in rats 
(44, 47), a relatively high dose of arsenite was singly administered orally into two 
animals at the same dose. Namely, three hamsters or rats per group (n=3) were orally 
administered arsenic (dissolved in purified water at a concentration of 0.5 mg As/mL) at 
a single dose of 5.0 mg As/kg body weight, and were euthanized at 1, 3, 5 and 7 days 
after the administration. Control rats were administered the same volume of water alone 
(10 mL/kg) as that in the experimental group. One group of hamsters and rats was 
housed in a metabolic cage to collect 24 hr-urine for 7 days, and then the animals were 
euthanized 7 days later.  
Whole Body Perfusion, and Sampling of Organs and Body Fluids. Whole body 
perfusion was performed according to the method developed in our laboratory (23). In 
brief, hamsters and rats under sodium pentobarbital anesthesia were dissected to expose 
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the heart for whole body perfusion, and then injected with heparin sodium solution 
(1,000 unit heparin sodium/mL/kg body weight) into the left ventricle. Heparinized 
blood was centrifuged at 3,000 g for 10 min to separate it into plasma and red blood 
cells (RBCs). Hamster and rat RBCs were washed three times with 50 mM Tris-HCl 
buffered saline (pH 7.4), hemolyzed with 4 volumes of extraction buffer (10 mM 
Tris-HNO3, pH 7.4, 25 ºC), mixed with a Vortex mixer for 5 min, and then centrifuged 
at 15,000 g for 30 min to obtain a supernatant fraction (RBC lysate). A 200 µL portion 
of the RBC lysate was heat-treated at 95 ºC for 10 min to denature catalase and then 
oxidized with 0.5 mL of 5 % H2O2 at room temperature for 12 hr to liberate arsenic 
bound to proteins as arsenate, MMAV or DMAV, and the reaction mixture was 
centrifuged at 800 g for 5 min to obtain supernatant for speciation analysis. On the other 
hand, fresh urine samples were centrifuged at 3,000 g for 10 min and then immediately 
subjected to analysis. Blood-free livers and kidneys were excised after whole body 
perfusion for speciation analysis and quantification. A 0.2 g portion of whole livers and 
kidneys (crushed organ) was heat-treated at 95 ºC for 10 min to denature catalase, and 
then oxidized with 0.5 mL of 5 % H2O2 for 12 hr to liberate arsenic bound to proteins as 
arsenate, MMAV or DMAV (23). The reaction mixtures were centrifuged at 800 g for 5 
min to obtain supernatants for speciation analysis. The concentrations of arsenic in 
organs and body fluids were determined by ICP-MS after wet-ashing with a mixed acid 
comprising concentrated nitric acid and 30 % H2O2 (v/v = 1). 
HPLC-ICP-MS Analysis. The HPLC system consisted of a liquid chromatograph 
solvent delivery pump (PU-610； GL Sciences Co., Tokyo), and a DG 660B-2 degasser 
(GL Sciences Co.). A polymer-based gel filtration column (Shodex Asahipak GS-220 
HQ, 300 mm x 7.6 mm i.d., Showa Denko, Tokyo) with an exclusion limit of 3000 Da, 
and an anion exchange column (Shodex Asahipak ES-502N 7C, 100 mm x 7.6 mm i.d., 
Showa Denko) were used to separate arsenic species in protein-free solutions. A 20 µL 
aliquot of a sample solution was applied to a GS or ES column, and then the column 
was eluted with 50 mM ammonium acetate buffer (pH 6.5 at 25 oC) or 15 mM citric 
acid buffer (pH 2.0 at 20 oC) at a flow rate of 0.6 or 1.0 mL/min. Arsenic in the eluted 
solution was monitored with an ICP-MS (HP4500; Yokogawa Analytical Systems, 
Hachiouji, Japan) at m/z 75. The signal at m/z 77 was also monitored to compensate for 
the molecular interference by ArCl+. On-line ICP-MS data were processed with 
software developed in house.  
LC-ESI-MS Analysis. The liquid chromatograph-electrospray ionization-mass 
spectrometer (LC-ESI-MS) consisted of an LCMS-2010EV series HPLC instrument 
(Shimadzu, Kyoto, Japan), and the ion source was used in both negative and positive 
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modes. Chromatography was performed on a gel filtration GS-220 HQ column with 
elution with 50 mM ammonium acetate buffer (pH 6.5, 25 oC) at a flow rate of 0.6 
mL/min, with an injection volume of 20 µL. Full scan LC-MS spectra were recorded, 
and the protonation and deprotonation of molecules were examined. 
1H NMR Measurements. A JEOL 400α(400 MHz) NMR instrument was used for 1H 
NMR experiments. Samples were dissolved in D2O plus D2SO4. 
Tautomeric Energies for the MeAs(=S)(OH)2/MeAs(=O)(OH)(SH) Pair.  
Data calculations were carried out according to the GAMESS quantum calculation 
package (42). The 6-31G(d,p) basis set was employed for all atoms. Geometry 
optimizations and subsequent single point energy calculations were carried out in the 
gas phase using the restricted Hartree-Fock (RHF) theory.  
Preparation of DMAIII and MMAIII by Reduction of DMAV and MMAV, 
respectively. DMAIII(Cys) and MMAIII(Cys)2 were synthesized in the forms 
coordinated with cysteine by reducing DMAV and MMAV, respectively, with a 5 molar 
equivalent of L-cysteine in distilled water at 90 °C for 1 hr. They were confirmed by 
comparison with those prepared from their iodide forms (37) in distilled water under a 
nitrogen atmosphere by HPLC-ICP-MS on a gel filtration GS-220 HQ column. 
DMAIII(Cys) and MMAIII(Cys)2 were dissociated to DMAIII and MMAIII, respectively, 
under the present column conditions (37). The methyl protons were detected at 1.26 and 
1.34 ppm in NMR data for DMAIII(Cys) and MMAIII(Cys)2 (in D2O), respectively, 
confirming methyl protons on trivalent arsenic (methyl protons in DMAV and MMAV 
were detected at 1.85 and 1.99 ppm (in D2O), respectively). 
Preparation of Mono- and Dimethylthioarsenicals by Reduction of MMAV and 
DMAV with Hydrogen Sulfide, Respectively. DMMTAV and DMDTAV were prepared 
according to the method reported elsewhere (23). MMMTAV was prepared by stepwise 
addition of H2SO4 to an aqueous solution of MMAV and Na2S to give a final molar ratio 
of MMAV: Na2S: H2SO4 = 1: 3: 4, followed by standing for 1 hr. MMMTAV in the 
reaction solution was purified on a Wako Gel 100 C18 column by elution with 10 mM 
ammonium acetate buffer (pH 6.5, 25 °C) for LC-ESI-MS analysis. 
  
38 
38 
Results 
 
Time-related Changes in Arsenic Concentrations in Organs and Body Fluids. The 
concentrations of arsenic (µg As/g organ or /mL fluid) in liver, kidney, blood (plasma 
and RBCs), and urine were determined at various times after an oral administration of 
arsenite, as shown in Figures 1 and 2, respectively. The arsenic concentration in hamster 
livers was significantly higher than that in rat livers at day 1 (3.2 and 0.16 µg As/g, 
respectively), as shown in Figures 1A and a. The arsenic concentration in the liver 
decreased to the control level by day 5 in hamsters, while it tended to be remained at an 
elevated level than the control level in rats. In the hamster kidneys, massive amounts of 
arsenic (3.7~4.6 µg As/g) were detected throughout, and it was 15-fold higher than the 
control level at day 7, as shown in Figure 1B. Although the renal arsenic content 
followed similar time-courses in rats and hamsters, the arsenic level in rats was lower 
than that in hamsters throughout, and the arsenic concentration in the kidneys decreased 
gradually with time in both animals (Figures 1B and b).  
The arsenic concentrations in hamster and rat plasma changed with time, as shown 
in Figures 1C and c. The concentration of arsenic was significantly higher in hamsters 
than in rats at day 1 (0.23 and 0.11 µg/mL, respectively). However, the arsenic 
concentration in hamsters decreased thereafter, whereas it tended to increase in rats.  
Arsenic recovered in rat RBCs at day 1 comprised more than 75 % of the dose, and 
the arsenic concentration continued to increase with days, i.e., to approximately 83 % of 
the dose at day 3 (Figure 1d). However, arsenic recovered in hamster RBCs comprised 
less than 0.8 % of the dose at day 1, and then decreased thereafter to the control level by 
day 3 (Figure 1D). Thus, it was confirmed that arsenic was hardly accumulated in RBCs 
in hamsters, but easily accumulated in RBCs in rats. 
On comparison of the time-related changes in the urinary arsenic concentration (µg 
As/mL) between the two animals (Figures 2A and a), a distinct difference can be seen. 
Namely, excretion of arsenic in urine took place mostly within one or two days after the 
administration in both animals. However, the excreted amount differed between the two 
animals, i.e., arsenic excreted in rats amounted to only 8 % of the dose by day 7, and 
decreased to a negligible (control) level after day 4. In contrast, approximately 63 % of 
the dose was excreted in hamsters by day 7, and arsenic continued to be excreted 
throughout, though decreasing with time, and had not decreased to the control level by 
day 7. The urinary volume at day 1 was decreased in hamsters, resulting in an elevated 
arsenic concentration probably due to a transient renal failure (Figure 2A).  
Arsenic Metabolites in Livers, Kidneys and RBCs Obtained from Hamsters and 
  
39 
39 
Rats after a Single Oral Administration of Arsenite. As arsenic metabolites in rats 
were shown to be bound mostly to soluble and non-soluble proteins in livers, kidneys 
and RBCs in the trivalent forms after an administration of arsenite in our previous 
experiments (23), and arsenic in livers and kidneys of hamsters was also mostly not 
extracted as free arsenic metabolites, arsenic metabolites in these samples were detected 
after oxidizing them to the corresponding pentavalent arsenicals (oxidized metabolites). 
For this reason, samples were heated to deactivate catalase, and then oxidized with 
H2O2 to liberate arsenic metabolites bound to proteins as oxidized free pentavalent 
forms. Thus, arsenic metabolites including those bound to soluble and non-soluble 
proteins were recovered in the soluble fraction as free pentavalent arsenicals, and then 
separated on an anion exchange ES-502 column. 
     Figure 3 shows the time-related changes in the arsenic profiles on an anion 
exchange column for the arsenic species recovered as the pentavalent forms from livers 
(A, a) and kidneys (B, b) after a single oral administration of arsenite to hamsters (A, B) 
and rats (a, b). Although distinct peaks were detected at the retention times of 
arsenobetaine (AsB), DMAV, MMAV and iAsV (most intense peak) for the oxidized 
hamster liver preparations at day 1 (Figure 3A), only small peaks of AsB, iAsV and 
DMAV (most intense peak) were detected for the oxidized rat liver preparations (Figure 
3a), reflecting their concentrations shown in Figure 1. It should be stressed that 
inorganic arsenic was the major metabolite (iAsIII detected as iAsV after oxidation) in 
hamsters, and continued to be detected until day 7 (Figure 3A). On the other hand, 
inorganic arsenic was detected marginally only at day 1 in rats, and MMA (MMAIII 
detected as MMAV after oxidation) was not detected. As a result, DMA remained as the 
major arsenic metabolite in the rat livers (Figure 3a). Contrary to the liver profiles, in 
the kidney profiles, inorganic arsenic peak was low or not detectable in both animals 
except for on day 1 in hamsters. There was a distinct difference in the arsenic 
metabolites in the kidneys between hamsters and rats; MMA was the major metabolite 
in hamsters (Figure 3B), while DMA was the major one in rats (Figure 3b), suggesting a 
difference in the capacity of second methylation from MMA to DMA between hamsters 
and rats.  
As arsenic in RBCs is also present in a form bound to proteins (38, 43), arsenic 
metabolites in the RBCs of hamsters (A) and rats (a) were detected after oxidizing them 
with H2O2, as shown in Figure 4. Three arsenic peaks were detected as oxidized forms 
for the hamster RBCs, MMAV being the major one, accompanied by minor DMAV and 
iAsV peaks, at day 1. However, these arsenic peaks decreased rapidly almost to the 
control levels by day 3 (Figure 4A). Contrary to arsenic in the hamster RBCs, only 
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DMAV was detected in the rat RBCs, and it remained throughout during the observation 
period, as shown in Figure 4a. Monomethylated arsenic was not detected in the rat 
RBCs, as already reported elsewhere (44, 45). The present observations suggest that 
arsenic in the form of MMAIII is taken up and stays only temporally in RBCs in 
hamsters, while DMAIII is taken up and retained for a long time in RBCs in rats.  
Detection of an Unknown Arsenic Metabolite in Hamster and Rat Urine. Figure 5 
shows chromatograms of arsenic in fresh urine collected from hamsters (Figures 5A and 
B) and rats (Figures 5a and b) daily for 7 days after a single oral administration of 
arsenite. Two different columns, anion exchange (Figures 5A and a) and gel filtration 
(Figures 5B and b) ones, were used. Although iAsV and MMAV were eluted at the same 
retention time on a gel filtration GS-220 column (Figure 5B and b), they were separated 
on an anion exchange ES-502 column (Figures 5A and a). On the other hand, although 
DMMTAV, DMDTAV and DMAIII were well separated on a gel filtration GS-220 
column (23.2, 18.7 and 29.8 min, respectively), they were not separated at all on an 
anion exchange ES-502 column (23, 43).  
The arsenic peaks for the hamster urine (Figure 5A) were detected in the order of 
elution from the anion exchange column; arsenobetaine (AsB), DMAV (main peak), 
MMAV, iAsIII, DMMTAV/DMDTAV, unknown peak (U), and iAsV. Although the 
arsenic concentrations were quite different between the urine of the two animals, the 
distributions of arsenic metabolites in the rat urine (Figure 5a) were similar to those in 
the hamster urine. Arsenate (iAsV) in the urine of both animals was eluted as unusually 
shaped peaks on an anion exchange column (Figures 5A and a). However, when iAsV 
fractionated on an anion exchange column was re-eluted on a gel filtration column, it 
was eluted as a peak of normal shape (data not shown), suggesting that iAsV may 
interact with urinary constituents causing unusually shaped peaks on an anion exchange 
column. AsB and DMAV detected in the control profiles are most likely of dietary 
origin.  
Although DMMTAV and DMDTAV were not separated, being detected as a single 
peak on an anion exchange column (Figure 5A), those in hamster urine on day 1 were 
clearly separated as distinct peaks on a gel filtration GS-220 column (Figure 5B). On 
the other hand, although DMMTAV was detected, DMDTAV was not for the rat urine on 
a gel filtration column (Figure 5b), suggesting further that DMMTAV but not DMDTAV 
was present in rat urine.  
The unknown metabolite (peak U) was detected in both animals with both columns, 
showing higher excretion in hamster urine than in rat urine. However, it was confirmed 
that trivalent MMAIII and DMAIII were not detected in fresh urine from both animals. 
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Namely, although MMAIII and DMAIII were eluted at the same retention time as those 
of the peak U compound and DMMTAV/DMDTAV, respectively, on an anion exchange 
column, they were separated on a GS-220 column, indicating the absence of both 
trivalent arsenicals in urine. Thus, DMMTAV and DMDTAV are likely to be mistaken 
for DMAIII when they are only compared on an anion exchange column. On the other 
hand, the peak U seems to be related to a monomethylthioarsenical as in the case of 
DMA to dimethylthioarsenicals. 
Correlation of an Unknown Arsenic Metabolite with a Reaction Product of MMAV 
Produced on Treatment with a Metabisulfite-thiosulfate Reagent. As the unknown 
arsenic metabolite (peak U compound) in urine was transformed to MMAV through 
oxidation with H2O2, it was assumed to be a derivative of monomethylated arsenic 
(MMA). Then, the peak U compound was compared with reaction products produced 
with MMAV and a metabisulfite-thiosulfate reagent (Reay and Asher method) (39). 
Namely, the urine sample collected from hamsters on day 1 and the reaction product 
were compared, as shown in Figure 6. The reaction product of MMAV named tentatively 
monomethylthioarsenical (MMTA) (it was found later to contain sulfur), was apparently 
not consistent with the urinary unknown arsenic metabolite on a GS-220 column 
(Figure 6, profiles A and B). However, when hamster urine was spiked with MMTA, it 
was co-eluted at the same retention time on a GS-220 column (Figure 6C). Furthermore, 
the unknown metabolite collected from hamster urine was eluted at the same retention 
time as that of the product MMTA, as shown in Figure 6D. In addition, the unknown 
metabolite was easily oxidized to MMAV on oxidation with 5 % H2O2 (on a GS-220 
column in Figure 6E) or an ES-502 column (data not shown)). These results indicated 
that although the unknown arsenic metabolite MMTA (peak U compound) was eluted 
differently from the synthetic MMTA due to the urinary matrix on a gel filtration 
column, it was identical with the synthetic MMTA. Thus, the unknown metabolite was 
correlated with the reaction product of MMAV produced through the reaction with the 
metabisulfite-thiosulfate reagent, as in the case of dimethylthioarsenicals (23). 
Identification of a Reaction Product of MMAV as MMMTAV by LC-ESI-MS and 
1H NMR Spectroscopy. The molecular weight and structure of MMTA were 
investigated by LC-ESI-MS, in the positive and negative ion modes, and 1H NMR. The 
molecular mass of MMTA was not obtained with the positive ion mode by LC-ESI-MS 
and FAB mass spectrometry (data not shown). However, it was detected clearly at m/z 
155 with the negative ion mode (Figure 7). 
The ratio of sulfur to arsenic for MMTA was determined with reference to those of 
dimethylthioarsenicals DMMTAV and DMDTAV, as shown in Table 1. The molar ratio 
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determined at m/z 75 (75As) and m/z = 34 (34S) or 48 (32S16O) indicated that the S/As 
ratio for MMTA is 1/1.   
The 1H NMR data (in D2O plus D2SO4) in Table 2 indicate that the chemical shift of 
methyl protons for MMTA (1.235 ppm) is more similar to that of pentavalent MMAV 
(1.317 ppm) than that of trivalent MMAIII (Cys) (0.731 ppm), suggesting that MMTA is 
a pentavalent form based on the NMR data. These 1H NMR data are consistent with 
those for dimethylthioarsenicals DMMTAV and DMDTAV (23). 
These MS and NMR data suggest that the structure of MMTA is either 
CH3As(=O)(SH)(OH) or CH3As(=S)(OH)2. The population ratio between the two 
tautomeric structures was estimated based on the theoretical difference for the energy. 
The results indicated a large negative energy difference (DE > -60.25 KJ/mol) between 
them, suggesting that the CH3As(=S)(OH)2 form is much more abundant than the 
CH3As(=O)(SH)(OH) form at the thermodynamic equilibrium. The population ratio of 
CH3As(=S)(OH)2 to CH3As(=O)(SH)(OH) appeared to be 310:1, suggesting that the 
unknown arsenic metabolite in the urine of hamsters and rats is CH3As(=S)(OH)2 
(monomethylmonothioarsonic acid; MMMTAV). 
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Discussion 
Although it has been said that there is an animal species-difference in the toxicity 
of arsenic, the mechanisms underlying the animal species-difference is not well 
understood, including the precise difference in the metabolism of arsenic. In the present 
study, it was clearly demonstrated that arsenic is distributed in organs and excreted into 
urine in manners highly dependent on animal species. The metabolic differences can be 
characterized and categorized into several groups as discussed below.  
It was demonstrated for the first time that monomethylthioarsonic acid 
(MMMTAV) is present in the urine of both hamsters and rats together with 
dimethylthioarsinic acids (DMMTAV and DMDTAV), though DMMTAV was detected 
only in rats. Since these urinary arsenic metabolites can be mistaken for trivalent mono- 
and dimethylated arsenicals (MMAIII and DMAIII, respectively), they have to be 
corrected to MMMTAV (present study) and DMMTAV (23), respectively, as also 
suggested by Feldmann’s group (36, 40). Our recent study on the metabolism of 
DMMTAV and DMDTAV in rats showed that thioarsenicals are distributed in organs 
and body fluids quite differently from non-thiolated arsenical DMAV, as also are the 
two dimethylthioarsinic acids (46). Namely, DMMTAV is readily taken up by rat RBCs 
and distributed more in organs than DMAV, whereas DMDTAV is much more readily 
excreted in urine than DMAV (38, 46). Thus, it was shown that DMMTAV is much more 
readily distributed in organs than DMAV. This is probably because DMMTAV is more 
stable chemically than DMAIII during the transport through bloodstream. These 
observations may explain why a pentavalent arsenical, DMMTAV, shows high toxicity 
(48). Although the metabolism and toxicity of MMMTAV are not known yet, those may 
show a different biological profile from that of pentavalent MMAV, as observed for 
DMMTAV. As not only DMMTAV but also MMMTAV was more abundantly detected 
in the present study in hamsters than in rats, DMMTAV and MMMTAV may play some 
roles in the toxicity of arsenic because of their possible preferential distributions among 
organs. 
Unlike in rats, in hamsters arsenic does not accumulate in the RBCs and is 
distributed to organs more extensively. As arsenic accumulating in rat RBCs is bound to 
hemoglobin in the form of a stable DMAIII-hemoglobin complex and excreted slowly in 
urine in rats, arsenic available in the body responsible for the toxicity seems to be much 
lower in rats than in hamsters. This may explain why rats are tolerant to arsenic despite 
that arsenic accumulates much heavily in them, or inversely why hamsters are thought 
to be sensitive to arsenic despite that arsenic is much readily excreted or not 
accumulated in them. 
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The present results also suggest that the methylation capacity, especially the second 
one from MMA to DMA, seems to be lower in hamsters than in rats, more MMA being 
recovered from the kidneys and RBCs, and more arsenic being excreted in urine in the 
form of MMA in hamsters. This lower methylation capacity seems to result in higher 
accumulation of a toxic form of arsenic, because MMAIII is supposed to be one of the 
proximate toxic forms in the metabolism of arsenic (49). In addition, as MMA rather 
than DMA was detected in hamster RBCs on day 1, arsenic metabolized in organs such 
as the liver is supposed to be excreted into the bloodstream, and then taken up by RBCs, 
as in the case of DMAIII in rats (47). Thus, in hamsters, slow methylation may result in 
more distribution of MMAIII in diverse organs. The higher recovery of MMA can be 
explained also by the preferential retention of MMA in organs of hamsters. 
MRP2/cMOAT transporter is known to be localized on the apical side of the 
hepatocytes, and the glutathione-conjugated forms of iAsIII and MMAIII can be excreted 
into the bile through this transporter (44, 50). As the source of MMAIII detected in 
hamster RBCs and MMAV excreted in hamster urine, glutathione-conjugated MMA 
may appear in the bloodstream through excretion through the MRP2/cMOAT 
transporter into the bile, followed by the enterohepatic circulation, or through direct 
excretion from the hepatocytes into the bloodstream through another unidentified 
organic anion transporter. However, it is not known at present how MMAIII appears in 
the bloodstream, i.e., directly through a transporter, through the enterohepatic 
circulation or through another pathways. 
The current study indicated that inorganic arsenic is methylated slower and 
retained longer in hamsters than in rats in the inorganic and MMA forms in both livers 
and kidneys. These observations suggest that excretion of inorganic arsenic is enhanced 
through a methylation process, supporting that methylation is a detoxification process. 
Dimethylated arsenic DMAIII is more labile and more easily released from 
arsenic-protein conjugates in organs than other trivalent forms, non-methylated iAsIII 
and monomethylated MMAIII, and more promptly excreted into urine than other arsenic 
species. The liver is known to be the major organ for arsenic methylation, and inorganic 
arsenic taken up by the liver is transformed to methylated metabolites through 
consecutive reductive methylation in the forms bound to proteins (23), and then finally 
excreted in urine in the form of pentavalent DMAV (24-26) for detoxification (27-29). 
These facts on methylation and excretion support that methylation is a detoxication 
pathway. However, recent studies have inversely suggested that the methylation of 
inorganic arsenicals is not a detoxicating event (19, 51), because MMAIII and DMAIII 
are more toxic than inorganic iAsIII in vivo and in vitro (49, 51). MMAIII and DMAIII 
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could be more potent than the corresponding pentavalent arsenic compounds, as also 
demonstrated by the DNA-damaging effects in vitro and in vivo with cultured cells (18, 
20, 52). However, as we suggested previously, trivalent arsenic compounds are mostly 
bound to sulfhydryl groups in proteins (not in free forms and less toxic forms) (23), and 
trivalent arsenic can be conjugated with glutathione for excretion, such as in bile in the 
forms of iAsIII(GS)3 and MMAIII(GS)2. Nevertheless, the major route is considered to be 
the transformation to DMAIII followed by excretion into the bloodstream rather than 
direct excretion through the biliary route (38, 43, 44). 
Arsenic accumulated and was retained in the kidneys of both animals, mostly in the 
form of MMAIII bound to proteins in the case of hamsters. This may be explained by 
that arsenic is methylated by independent two methyltransferases in different organs. 
Buchet and Lauwerys (53) indicated that arsenic methylation occurs in two steps with 
two different enzymes. Moreover, Drobna et al. (54) suggested that the production and 
accumulation of MMAIII were key factors contributing to the toxicity of acute arsenic 
exposure. On the other hand, marmoset monkeys and chimpanzee (which lack arsenic 
methyltransferases) have been shown not to methylate inorganic arsenic, and most 
arsenic accumulates in their livers in inorganic forms (8) and is retained for a long 
period (55). Because trivalent arsenic exhibits high affinity to sulfhydryl groups on 
proteins (23, 26, 55, 56), it inhibits the activities of enzymes such as glutathione 
reductase (57, 58), glutathione peroxidases (59), thioredoxin reductase (60), and 
thioredoxin peroxidase (61). Thus, arsenic toxicity may be relieved by releasing 
arsenicals from protein-bound forms (including enzymes) by methylating arsenic.  
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Table 1. The ratio of sulfur to arsenic in thioarsenicals. 
 
 
 
 
        MMMTAV DMMTAV DMDTAV 
 75As (µmol)  72   62    63 
 34S (µmol)  81   56    123 
 34S/75As         1.1   0.9    1.9   
The contents of S and As in each thioarsenical were estimated 
from the 75As and 34S profiles on HPLC-ICP-MS with reference 
to the standard peak areas of arsenate and sodium sulfate.   
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Table 2. Chemical shifts of methyl protons of methylated arsenicals in 1H NMR 
spectra.  
 
 
 
Arsenical          Chemical shift (ppm) 
MMAV                         1.317 
MMAIII (Cys)2                         0.731 
MMMTAV                         1.235        
MMAIII(Cys)2 was prepared by reducing MMAV with Cys. 
Arsenic compounds were dissolved in D2O plus D2SO4 for 
NMR measurement. 
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Figure 1. Time-related changes in the concentration of arsenic and percentage of dose in 
organs (liver/kidneys) and body fluids (plasma/RBCs) after a single oral administration 
of arsenite to hamsters and rats. Male hamsters (A-D) and Wistar rats (a-d) were orally 
administered iAsIII at a single dose of 5.0 mg of As/kg body weight, and sacrificed 1, 3, 
5 or 7 days later. The heparinized blood was centrifuged at 3,000 g for 10 min to 
separate it into plasma and red blood cells (RBCs). Organs were dissected after whole 
body perfusion, and the concentrations of arsenic in organs and body fluids were 
determined by ICP-MS after ashing with HNO3 and H2O2. The concentrations of arsenic 
(columns) and percentage of dose (line graphs) are shown for livers (A and a), kidneys 
(B and b), plasma (C and c), and RBCs (D and d) of hamsters and rats, respectively. 
Control samples were prepared from hamsters and rats with administration of the same 
volume of water alone. Data are expressed as means ± SD (n=3).
hamst rat 
hamst rat 
hamst rat 
hamst rat 
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Figure 2. Time-related changes in the concentration of arsenic and percentage of 
dose in urine after a single oral administration of arsenite to hamsters and rats. 
24-hr-Urine was collected from hamsters and rats for 7 days after an oral administration 
of iAsIII at a dose of 5.0 mg As/kg body weight. The urine samples were centrifuged to 
remove non-soluble matters and then stored at –50 ºC until use. The concentrations of 
arsenic in the hamster (A) and rat (a) urine were determined by ICP-MS after ashing 
with HNO3 and H2O2. The data are shown as concentrations of arsenic (columns) and 
cumulative recoveries relative to the dose (line graphs). Control urine was collected 
from hamsters and rats administered with the same volume of water alone. Data are 
expressed as means ± SD (n=3). 
 
 
(A) hamster urine (a) rat urine 
Time after administration (day) 
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Figure 3. Time-related changes in the distribution of arsenic in liver (A, a) and 
kidneys (B, b) of hamsters (A, B) and rats (a, b) after oxidation of arsenic 
metabolites with H2O2 by HPLC-ICP-MS on an anion exchange column. 
Livers (A and a) and kidneys (B and b) were obtained from hamsters (A and B) and rats 
(a and b) as described in the legend to Figure 1. A 0.2 g portion of livers and kidneys 
(crushed organs) was heat-treated at 95 °C for 10 min to denature catalase, and then 
oxidized with 0.5 mL of H2O2 (5%) for 12 hr. The reaction mixtures were centrifuged at 
800 g for 5 min to obtain supernatants, which were then subjected to speciation analysis 
by HPLC-ICP-MS on an anion exchange ES-502N 7C column. Control livers and 
kidneys were obtained from hamsters and rats given water alone. 
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Figure 4. Time-related changes in the distributions of arsenic in hamster (A) and 
rat RBCs (a) after oxidation of arsenic metabolites with H2O2 by HPLC-ICP-MS 
on an anion exchange column. 
Red blood cells (RBCs) were obtained from hamsters (A) and rats (a) as described in 
the legend to Figure 1. A 20 % lysate was prepared by hemolysing RBCs in 10 mM 
Tris-HNO3 (pH 7.4), followed by centrifugation at 15,000 g for 30 min. A 0.2 mL 
portion of the supernatant was heat-treated at 95 °C for 10 min, and then oxidized with 
0.5 mL of H2O2 (5%) for 12 hr. The reaction mixture was centrifuged at 800 g for 5 min 
to obtain the soluble fraction, and then subjected to HPLC-ICP-MS analysis on an anion 
exchange ES-502N 7C column. Control RBC lysates were obtained from hamsters and 
rats administered water alone. 
Retention time (min) Retention time (min) 
MMAV 
iAsV 
DMAV 
DMAV 
10 7.5 5 2.5 10 7.5 5 2.5 
(A) hamster RBC (a) rat RBC 
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Figure 5. Time-related changes in the arsenic distribution in urine after a single 
oral administration of arsenite to hamsters and rats by HPLC-ICP-MS on gel 
filtration and anion exchange columns. 
24-hr-Urine was collected daily for 7 day (1-7D), as described in the legend to Figure 2. 
The distributions of urinary arsenic metabolites in hamsters (A and B) and rats (a and b) 
were determined on an anion exchange ES-502N 7C column (A and a) and on a gel 
filtration GS-220 HQ column (B and b) by HPLC-ICP-MS. Control urine was collected 
from hamsters and rats administered water alone.  
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Figure 6. Comparison of an unknown arsenic metabolite in urine with a reaction 
product of MMAV by the Reay and Asher method. 
Standard monomethylated thioarsenical MMTA (A) was prepared by reacting MMAV 
with a metabisulfite-thiosulfate reagent. On the other hand, the first 24-hr-urine (B) was 
collected from hamsters as described in the legend to Figure 2, and then spiked with the 
standard MMTA (C = A + B). An unknown arsenic metabolite in the first 24 hr urine of 
hamsters in panel B was fractionated on a gel filtration GS-220 HQ column, and then  
re-chromatographed (D). The separated MMTA fraction corresponding to the profile D 
was treated with 5% H2O2 (E). The distributions of arsenic (A-E) were determined by 
HPLC-ICP-MS on a gel filtration GS-220 HQ column. 
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Figure 7. Mass spectrum of MMMTAV with a liquid chromatograph-electrospray 
ionization-mass spectrometer (LC-ESI-MS). 
MMMTAV was prepared by stepwise addition of H2SO4 to an aqueous solution of 
MMAV and Na2S to give a final molar ratio of MMAV: Na2S: H2SO4 = 1: 3: 4, followed 
by standing for 1 hr. MMMTAV in the reaction solution was purified by open column 
chromatography on Wako Gel 100 C18 Gel. The purified MMMTAV was subjected to 
LC-ESI-MS, in the negative ion mode. Chromatography was performed on a gel 
filtration GS-220 column by elution with 50 mM ammonium acetate buffer (pH 6.5, 
25 °C) at a flow rate of 0.6 mL/min. The data showed peaks at m/z 155 [M-H]-, m/z 215 
[M+CH3COO]-, and m/z 311 [2M-H]-. 
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Chapter 3. 
 
Toxicity of Dimethylmonothioarsinic Acid toward Human  
Epidermoid Carcinoma A431 Cells 
 
 
Abstract 
Chronic ingestion of arsenic-contaminated drinking water induces skin lesions and 
urinary bladder cancer in man. It is now recognized that thioarsenicals such as 
dimethylmonothioarsinic acid (DMMTAV) are commonly excreted in the urine of man 
and animals, and that the production of DMMTAV may be a risk factor for the 
development of the diseases caused by arsenic. The toxicity of DMMTAV was 
compared with that of related non-thiolated arsenicals as to cell viability, uptake ability, 
generation of reactive oxygen species (ROS), and cell cycle progression of human 
epidermoid carcinoma A431 cells, arsenate (iAsV), arsenite (iAsIII), dimethylarsinic acid 
(DMAV) and dimethylarsinous acid (DMAIII) being used as reference non-thiolated 
arsenicals. DMMTAV (LC50=10.7 µM) was shown to be much more cytotoxic than iAsV 
(LC50=571 µM) and DMAV (LC50=843 µM), and it’s potency being close to that of 
trivalent arsenicals iAsIII (LC50=5.49 µM) and DMAIII (LC50=2.16 µM). The greater 
cytotoxicity of DMMTAV was associated with greater cellular uptake/distribution, and 
intracellular ROS remarkably increased in A431 cells on exposure to DMMTAV than to 
other trivalent arsenicals at the respective LC50. Exposure of DMMTAV to cells for 24 h 
induced cell cycle perturbation. Namely, cells residing in S- and G2/M-phases increased 
from 10.2 and 15.6 % to 46.5 and 20.8 %, respectively. These results suggest that 
although DMMTAV is a pentavalent arsenical, it is taken up efficiently by cells and 
causes various levels of toxicity, differently from non-thiolated pentavalent arsenicals, 
demonstrating that DMMTAV is one of the most toxic arsenic metabolites. The high 
cytotoxicity of DMMTAV was explained/proposed by 1) efficient uptake by cells 
followed by 2) it’s transformation to DMAV, 3) producing ROS in the redox equilibrium 
between DMAV and DMAIII in the presence of glutathione. 
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Introduction  
Chronic ingestion of arsenic-contaminated drinking water is associated with an 
increased risk of cancer to man, such as carcinomas of the skin, lungs and urinary 
bladder (1, 2). Ingested inorganic arsenic is transformed metabolically into methylated 
metabolites in man and animals, and then excreted in the urine mostly in the form of 
dimethylated metabolite dimethylarsinic acid (DMAV) (3-5). However, little is known 
about the mechanisms underlying arsenic-induced carcinogenicity in the target organs. 
It remains unknown which arsenic species are involved in and responsible for the 
observed arsenic toxicity and carcinogenesis. 
Mutation is known to lead to neoplastic transformation, and the genotoxic 
potential of arsenic has been extensively explored. Recently, several researchers 
indicated that trivalent arsenicals are much more cytotoxic than pentavalent ones, and 
induce much oxidative DNA damage and a greater frequency of chromosomal 
aberrations in vitro (6-10). On the other hand, the skin is one of the identified target 
tissues for arsenic toxicity. This is potentially due to the high affinity of arsenic to 
sulfhydryl groups, which leads to arsenic accumulation and retention in keratin-rich 
skin tissue (11). In arsenic-induced skin cancer in man, common symptoms include 
keratosis and hyperkeratosis, which are consistent with increased cell proliferation. 
Recently, reactive oxygen species (ROS) have been considered to play an important role 
in these diseases (12), because the generation of ROS is associated with DNA damage 
(single and double strand DNA breaks) and deletion mutations. Thus, ROS can damage 
tumor suppressor genes or enhance the expression of proto-oncogenes, and cells may go 
on to become tumor cells (13, 14). A number of studies have also shown that the 
generation of hydroxyl radicals mainly causes DNA damage in keratinocytes on 
treatment with arsenite (12, 15). 
In mammals, inorganic arsenic is known to be taken up firstly by the liver and 
rapidly bound to proteins, and then converted to monomethylarsonous acid (MMAIII) 
and dimethylarsinous acid (DMAIII) through consecutive reductive methylation in forms 
bound to proteins (16), finally being excreted in the urine mostly in the form of 
dimethylarsinic acid (DMAV) for detoxification (17, 18). Recent studies indicated that 
the arsenic metabolite DMAV is a primary carcinogen in mammals (19). Long-term 
exposure to DMAV in drinking water or the diet can induce bladder cancer in rats. 
Yoshida et al. reported that sulfur-containing arsenic compounds were clearly detected 
in rat urine after long-term oral administration of DMAV, MMAV, iAsIII or 
trimethylarsine oxide (TMAO), suggesting that sulfur-containing arsenicals might play 
an important role in arsenic carcinogenesis (20). 
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A urinary sulfur-containing arsenic metabolite was identified as 
dimethylmonothiarsinic acid (DMMTAV) by Feldmann’s (21, 22) and our (23, 24) 
groups. Then, DMMTAV, dimethyldithioarsinic acid (DMDTAV), and 
monomethylmonothioarsonic acid (MMMTAV) were found to be common in the urine 
of arsenic-exposed man and animals (22, 24). However, these thioarsenicals have been 
mistaken as trivalent arsenicals DMAIII and monomethylarsonous acid (MMAIII) 
(25-29). As for the production of thioarsenicals, we suggested that thiolation takes place 
in red blood cells (RBCs) in animals (unpublished observations), and that thioarsenicals 
are detected more abundantly in the urine of arsenic-sensitive species, hamster, than in 
an arsenic-tolerant species, rat (24). On the other hand, our previous study showed that 
DMMTAV is distributed in organs and body fluids quite differently from non-thiolated 
arsenicals DMAV and MMAV. Namely, DMMTAV is readily taken up by RBCs in rats 
and distributed more in organs in a manner similar to trivalent DMAIII, whereas 
DMDTAV is more readily excreted in the urine in its intact form (30). Although 
DMMTAV is chemically much more stable than DMAIII, it has been suggested to be 
toxic (31). However, little is known about the molecular mechanisms and toxicological 
significance of thioarsenicals. 
Although skin cancer is one of common tumors associated with arsenic exposure, 
little information is available on the effect of DMMTAV on human skin cells. In the 
present study, we focused on the toxic effect of DMMTAV on cell viability, uptake 
ability, ROS production and cell cycle progression in relation to the distribution of 
arsenic in human epidermoid carcinoma A431cells in comparison with those of iAsIII, 
iAsV, DMAV and DMAIII.  
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Material and Methods 
 
Reagents. 
All reagents were of analytical grade. Milli-Q water (Millipore) was used throughout. 
Trizma® HCl and Trizma® Base were purchased from Sigma (St. Louis, MO, USA). 
Nitric acid, hydrogen chloride, sodium sulfide (Na2S), ammonium acetate, acetic acid, 
and a 28 % ammonia solution, L-cysteine, sodium arsenite (iAsIII), sodium arsenate 
(iAsV), and dimethylarsinic acid [(CH3)2AsO(OH)] (DMAV) were purchased from Wako 
Pure Chemical Industries, Ltd. (Osaka, Japan). An MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay kit was purchased 
from Promega Corporation (Tokyo, Japan), and hydroxypheyl fluorescein (HFP) from 
Invitrogen (Tokyo). The arsenic standard solution (1,000 µg/mL) for ICP MS was 
purchased from SPEX CentiPrep (Metuchen, NJ, USA). Stock solutions of all arsenic 
compounds (10 mmol/L) were prepared from the respective standard compounds. All 
stock solutions were stored in the dark at 4° C. Diluted standard solutions for analysis 
were prepared daily prior to use.   
HPLC-ICP MS analysis. 
The HPLC system consisted of a liquid chromatograph solvent delivery PU-610 pump 
and a DG 660B-2 degasser (GL Sciences Co., Tokyo). A polymer-based gel filtration 
column (Shodex Asahipak GS-220 HQ, 300 mm x 7.6 mm i.d., Showa Denko, Tokyo) 
with an exclusion limit of 3000 Da was used to separate unbound arsenic species from 
protein-bound forms. A 20 µL aliquot of a sample solution was applied to a column, and 
then the column was eluted with 50 mM ammonium acetate buffer (pH 6.5 at 25° C) at 
the flow rate of 0.6 mL/min. Arsenic in the eluate was monitored with an ICP MS 
(HP4500; Yokogawa Analytical Systems, Musashino, Japan) at m/z 75. The signal at m/z 
77 was also monitored to compensate for the molecular interference by ArCl+. On-line 
ICP MS data were processed with software developed in house. 
Culture of A431 cells. 
A431 cells (human epidermoid carcinoma cells) were obtained from the JCRB Cell 
Bank (Osaka, Japan). Cells were seeded at a density of 1.0×106 in a 10 cm dish, and 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) of the high glucose 
type (4,500 mg/L), supplemented with 10 % fetal bovine serum (FBS), 100 U/mL of 
penicillin, and 100 mg/mL of streptomycin, at 37° C under a 5 % CO2 atmosphere. 
Twenty-four hours after seeding, cultures were washed twice with phosphate-buffered 
saline (PBS) to remove unadhered cells, fresh medium (FBS free) supplemented with 
insulin (5 µg/mL) and recombinant epidermal growth factor (EGF) (0.1 ng/mL) was 
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added, and then the cells were treated with iAsIII, iAsV, DMAIII, DMAV or DMMTAV 
for 24 h. 
MTT assay for cellular viability. 
A431 cells were seeded at a density of 3×104 cells/100 µL/well on 96-well culture 
plates (Promega Corporation). Twenty-four hours after seeding, the cultures were 
washed twice with PBS to remove unadhered cells, and then exposed to various 
concentrations of arsenic compounds for 24 h in FBS-free medium. Then, 20 µL of an 
MTT solution was added to each well and the plates were incubated for an additional 3 
h at 37° C. Cell viability was measured as the absorbance at 490 nm with a microplate 
reader and expressed as a percentage of the control level. 
Cell cycle analysis 
The cell cycle was examined by flow cytometry. After treatment with arsenicals for 24 
h (at the LC50), 1×106 cells were collected by trypsin digestion and centrifugation, 
fixed in 70 % ethanol at 4° C for 2 h, and then washed with PBS. After RNase (2 
mg/mL) treatment at room temperature for 15 min, the cells were stained with 50 
µg/mL propidium iodide (PI) at 4° C for 30 min. The PI-elicited fluorescence of 
individual cells was measured (20,000 cells were analyzed in total for each sample) by 
flow cytometry using a Beckman-flow cytometer (EPICS ELITE ESP). Data were 
analyzed with WIN MDI software (Windows multiple document interface for flow 
cytometry: http://facs.scripps.edu). 
Measurement of reactive oxygen species (ROS) 
The amounts of intracellular ROS (hydroxyl radical) were determined by flow 
cytometry. Twenty-four hours after treatment with arsenicals (at the LC50), 1×106 cells 
were collected by trypsin digestion and centrifugation, and then washed with PBS. 
Hydroxyphenyl fluorescein (HPF) was used to detect highly reactive oxygen species 
(hROS), i.e., hydroxyl radicals, selectively by adding it to the cells to a final 
concentration of 5 µM at 4° C for 30 min. The HPF-elicited fluorescence of individual 
cells was measured (a total of 20,000 cells were analyzed for each sample) by flow 
cytometry using a Beckman-flow cytometer. Data were analyzed with WIN MDI 
software. 
Preparation of DMAIII and dimethylmonothioarsinic acid (DMMTAV) 
DMAIII was prepared by reduction of DMAV with cysteine according to the method 
reported elsewhere (24). 
DMMTAV was prepared by stepwise addition of concentrated H2SO4 to an 
aqueous solution of 38 mM DMAV and 60 mM Na2S to a final molar ratio of DMAV : 
Na2S : H2SO4 = 1 : 1.6 : 1.6, the reaction solution being allowed to stand for 1 h. 
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DMMTAV was extracted with diethylether (16, 32). Crystallized DMMTAV was 
disolved in buffer solution for use.  
Arsenic measurements 
Cells were seeded at a density of 1.0×106 in a 10 cm culture dish (n=3), and then 
exposed to arsenic compounds (in FBS-free medium). After exposure, the cell 
monolayer was washed twice with PBS. The cells were collected and then suspended in 
300 µL of a 100 mM ammonium acetate solution (pH 6.5 at 25° C. dissolved oxygen 
was purged by bubbling with 99.999% nitrogen gas). The suspended cells were 
disrupted with an ultrasonic homogenizer (Biorupter® UCD-200. Cosmo Bio Co., Ltd, 
Tokyo) on ice at 200 W and 20 kHz for 30 seconds three times with intervals of 45 
seconds, followed by centrifugation at 105,000 g for 1 h at 4° C to obtain supernatant 
(soluble fraction) and non-soluble sediment fractions. The concentrations of arsenic in 
the supernatant and non-soluble fractions were determined with an ICP MS (HP 4500) 
after wet-ashing with a mixture of concentrated nitric acid and 30 % H2O2 (v/v = 1) at 
150° C for 2 days.  
Statistical analysis 
Each experiment was performed at least three times. Statistical analysis of data was 
carried out using Student’s t-test, and the data were expressed as mean±SD. 
Differences between the two groups were regarded as significant at p<0.05, and 
significant differences were labeled by asterisks (*). 
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Results 
 
Effect of DMMTAV in comparison with other arsenicals on the viability of A431 cells  
As shown in Figure 1, iAsIII, iAsV, DMAV, DMAIII and DMMTAV inhibited the growth 
of A431 cells in a concentration-dependent manner. The LC50 values for non-thiolated 
pentavalent arsenicals iAsV and DMAV, and trivalent iAsIII and DMAIII were calculated 
to be 571 and 843, and 5.49 and 2.16 µM, respectively (Fig. 1A-D). Although 
DMMTAV is a pentavalent arsenical, it markedly suppressed the growth of A431 cells, 
and the LC50 value was calculated to be 10.7 µM (Fig. 1E). These data indicated that 
thiolated pentavalent DMMTAV is much more toxic than other pentavalent 
non-thiolated arsenicals.  
 
Effect of DMMTAV on cell cycle arrest of A431 cells 
Although trivalent arsenicals iAsIII and DMAIII interfered with cell cycle progression at 
concentrations corresponding to the respective LC50 values, the effects were limited. On 
the other hand, DMMTAV induced S- and G2/M-phase cycle much more significant 
arrest (Figure 2). In the untreated group, A431 cells residing in the G1, S- and 
G2/M-phases amounted to 80.5, 7.3 and 12.2%, respectively. However, after exposure 
of A431 cells to its LC50 for 24 h, DMMTAV showed the most significant effect, the 
G1-phase fraction being decreased to 38.1%, and those of the S- and G2/M-phases 
being increased from 7.3 and 12.2 % to 41.3 and 20.6%, respectively. Thus, the 
percentage of cells residing in the S- and G2/M-phases in the experimental groups were 
increased 6 and 2 times, respectively, compared to those of the control group. There 
were no significant changes in cell cycle progression on exposure to iAsV and DMAV 
for 24 h at the respective LC50 values, the effects being similar to those in the case of 
the control group (data not shown). These results suggested that DMMTAV has a much 
stronger effect on cell cycle progression than other trivalent and pentavalent arsenic 
compounds.  
 
Effect of DMMTAV on cellular ROS production in A431 cells 
To confirm the generation of ROS in A431 cells after arsenic treatment, cells were 
preloaded with 5 µM hydroxyphenyl fluorescein (HPF) for 30 min at 37° C, and then 
exposed to each arsenical at its LC50 value for 24 h, as shown in Figure 3. Mean HPF 
fluorescence increased from 104.4 (control) to 120 and 161.3 on treatment with iAsIII 
and DMMTAV, respectively, suggesting that DMMTAV more markedly increased the 
production and intracellular accumulation of ROS than iAsIII. On the other hand, 
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treatment with DMAIII did not produce a significant level of ROS (hydroxyl radicals) in 
A431 cells.  
 
Uptake of DMMTAV in comparison with other arsenicals by A431 cells 
The uptake of arsenic compounds was examined in cultures of A431 cells by incubation 
with the arsenicals at the respective LC50 values for up to 24 h (iAsV and DMAV were 
used at the same concentrations as the corresponding trivalent arsenicals). Figure 4 
shows that the total intracellular arsenic concentrations were 7 and 14 times higher in 
iAsIII- and DMAIII-exposed cells than in the corresponding pentavalent iAsV- and 
DMAV-exposed ones, respectively. It is also evident that pentavalent iAsV and DMAV 
were taken up little by A431 cells. However, as phosphate was present in the medium at 
a concentration of approximately 1 mM, the lower uptake of iAsV compared with iAsIII 
may partly be due to the competition with phosphate. On the other hand, pentavalent 
thiolated DMMTAV was taken up significantly in A431 cells in a manner similar to in 
the case of trivalent arsenicals rather than non-thiolated pentavalent arsenicals. 
Although both trivalent arsenicals recovered in cells were mostly distributed in the 
non-soluble fraction, most arsenic of DMMTAV origin was recovered in the soluble 
fraction. These results suggested that DMMTAV was taken up efficiently by cells and 
distributed in cells differently from trivalent arsenic compounds.  
 
Distribution of arsenic in the soluble fraction of A431 cells after exposure to DMMTAV 
in comparison with other arsenicals 
Figure 5 shows the distributions of arsenic in the soluble fractions of A431 cells 
obtained 24 h after treatment with trivalent iAsIII and DMAIII, and pentavalent iAsV, 
DMAV and DMMTAV, as determined on a gel filtration GS-220 column by HPLC-ICP 
MS. The arsenic distributions reflected the concentrations of the arsenicals recovered in 
the soluble fraction shown in Figure 4. Only small arsenic peaks, such as those of iAsV 
and DMAV, were detected for the soluble fractions of A431 cells after treatment with 
iAsV and DMAV, and arsenic bound to proteins (void volume) was not detected in the 
profiles of these pentavalent arsenicals, suggesting that non-thiolated pentavalent 
arsenicals were hardly taken up by the cells, and those taken up slightly by the cells 
were present in their intact forms. 
On the other hand, arsenic distributed in the soluble fractions after treatment 
with trivalent iAsIII and DMAIII was detected at the void volume (arsenic bound to 
proteins) together with iAsIII (small) and DMAV peaks (Figure 5). In contrast to 
non-thiolated pentavalent arsenicals, arsenic of DMMTAV origin was abundant in the 
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soluble fraction and detected as a huge DMAV peak together with that bound to proteins 
(void volume). However, further thiolated dimethyldithioarsinic acid (DMDTAV) and 
intact form DMMTAV peaks were not detected, suggesting that most DMMTAV was 
hydrolyzed to DMAV immediately after it had been taken up by the cells or bound to 
proteins. 
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Discussion 
 
In the present study, we investigated the toxicity of thiolated pentavalent 
DMMTAV toward human epidermoid carcinoma A431 cells. Although DMMTAV is a 
pentavalent arsenical, it was shown to be more cytotoxic than non-thiolated pentavalent 
arsenicals, and to be similar to that of trivalent arsenicals rather than to that of 
non-thiolated pentavalent arsenicals. Namely, trivalent arsenicals (iAsIII and DMAIII) 
showed cytotoxic effects in a low micro molar (µM) concentration range, whereas 
pentavalent non-thiolated arsenicals (iAsV and DMAV) showed cytotoxic effects at two 
orders of magnitude higher concentrations. Thus, it was confirmed that pentavalent 
thiolated arsenical DMMTAV is toxic at a comparable level with that of trivalent 
arsenicals. Recently, Ralm et al (22) also reported that the toxicity of DMMTAV is much 
higher than non-thiolated dimethylarsenical DMAV. However, the LC50 value was one 
order lower than our present results, probably due to differences in cell types and/or 
experimental conditions employed. 
Tumor formation in vivo is correlated with changes in the expressions of 
multiple genes. ROS cause damage to tumor suppressor genes or enhance the 
expression of proto-oncogenes (14). Recently, oxidative stress was proposed to be a 
possible mode of carcinogenic action of arsenic (33). Also, the mutagenesis and DNA 
damage caused by ROS contribute to the initiation of cancer, because ROS-induced 
DNA damage involves an attack at the C8 carbon atom of 2’-deoxyguanine yielding 
8-hydroxyl-2’-deoxyguanine (8-OHdG), and then causes mispairing during 
DNA-replication, giving rise to a G to T conversion and thereby resulting in mutation. 
Yamanaka et al. (34) reported that the level of 8-OHdG was specifically enhanced in 
target organs such as the skin, lungs and urinary bladder when mice were administered 
DMAV orally. Hughes et al. (35) also reported that after daily exposure for 10 days to 
inorganic arsenate (iAsV), arsenic distributed in target organs such as the bladder was 
mostly in the form of dimethylated arsenical DMA. These observations indicated that 
dimethylated arsenical DMA tends to accumulate selectively in target organs and tissues, 
and can induce DNA damage. The present observations as to the efficient production of 
ROS on exposure to DMMTAV suggest a role of DMMTAV in causing toxicity of 
arsenic such as in carcinogenesis. Furthermore, as DMMTAV taken up by cells was 
present mostly in the form of DMAV, differently from that in the case of DMAIII, 
intracellular DMAV is supposed to have an important role in causing the toxicity 
through the production of ROS. Thus, although extracellular DMAV (DMAV in culture 
medium) is less toxic than the corresponding trivalent one, intracellular DMAV is 
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supposed to be highly toxic by producing ROS. We propose the mechanism underlying 
the production of ROS through the redox equilibrium between DMAV and DMAIII in 
the presence of GSH, as schematically represented in Figure 6.  
Our present study revealed that pentavalent thioarsenical DMMTAV induced 
much more significant effects on cell cycle perturbation than trivalent arsenicals in 
A431 cells, suggesting that DMMTAV has a strong effect on the cell cycle of A431 cells. 
Similar results were obtained by treatment with arsenite to a human-derived epithelial 
bladder cancer cell line but at much higher doses (36). Thus, thioarsenical DMMTAV 
may be one of the most potent toxic arsenic metabolites and may induce skin lesions 
and/or bladder cancer. 
Thioarsenical DMMTAV is chemically more stable than trivalent DMAIII, and is 
detectable commonly in the urine of man and animals in response to exposure to arsenic 
(22, 24), suggesting that DMMTAV may be more easily distributed in the skin and 
urinary bladder than non-thiolated toxic arsenic metabolites such as DMAIII and MMAIII. 
In fact, the present study indicated that DMMTAV is taken up by A431 cells much more 
efficiently than non-thiolated pentavalent arsenicals, the efficiency being similar to that 
in the case of trivalent arsenicals. Hirano et al. (37) and Dopp et al. (38) reported that 
the higher toxicity of trivalent arsenic compounds compared to that of pentavalent ones 
can be explained at least in part by the more efficient uptake rate of trivalent arsenic 
compounds by cells. The large difference in the toxicity of organic arsenicals between 
the two valence states may be due to the cellular accumulation rate and potency to 
induce oxidative stress (ROS). We observed that generation of ROS (hydroxyl radicals) 
in cells with iAsIII was significantly lower than on treatment with DMMTAV at the 
respective LC50 values. However, the generation of ROS was not increased in the cells 
on treatment with DMAIII. Therefore, it is considered that the cell death was not due to 
ROS produced on treatment with DMAIII, suggesting that the mechanisms underlying 
cell death are different from those in the case of DMMTAV. In fact, under the same 
conditions (with the same LC50 values), generation of ROS was significantly higher in 
cells on treatment with DMMTAV than with DMAIII, and the amount of DMMTAV 
taken up by cells was significantly higher than those of other arsenic species. These 
results suggest that efficient uptake by cells is essential to cause the toxicity, and the 
distribution of arsenic in cells, i.e., bound to proteins in the sediment fraction or free 
DMAV form in the soluble fraction, may determine the toxicity, trivalent DMAIII or 
pentavalent DMMTAV type. However, the discrepancy in the production of ROS and 
the toxicity between trivalent DMAIII and pentavalent DMMTAV remained to be 
clarified further to characterize the toxicological significance of DMMTAV.  
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Trivalent arsenicals are known to be highly toxic and reactive to thiol groups on 
proteins, and to inactivate important SH–enzymes (39). Our present study revealed that 
although trivalent arsenicals were distributed in the soluble and mostly in the 
non-soluble fractions in forms bound to proteins in cells, DMMTAV was distributed 
mainly in the soluble fraction partly in forms bound to proteins but mostly in the free 
DMAV form. Thus, DMMTAV taken up efficiently by cells is assumed to be bound to 
proteinous thiol groups similarly to GSH (22) and/or after being reduced to DMAIII. 
However, major portions of DMMTAV is thought to be hydrolyzed to DMAV. The 
difference in the distribution pattern of arsenic in cells between DMMTAV and trivalent 
arsenicals seems to explain the difference in the cytotoxicity between the two types of 
arsenicals. In conclusion, although DMMTAV found in man and animals is a minor 
metabolite, it is highly toxic and may cause cancer. 
Summarizing the present observations, dimethylmonothioarsenical DMMTAV is 
much efficiently taken up by cells and mostly distributed in the soluble fraction in the 
form of DMAV. The high cytotoxicity of DMMTAV can be explained by the production 
of ROS through the redox equilibrium between DMAV and DMAIII in the presence of 
GSH, as schematically presented in Figure 6. The present observations can be supported 
by our previous ones that inorganic arsenic is methylated in the forms bound to proteins 
and free DMAV may not be present or present only little during the metabolism of 
arsenic in organs (16), suggesting that the presently proposed free DMAV is not present 
in cells during the metabolism of inorganic arsenic. Thus, it can be proposed that 
although extracellular DMAV is not toxic because of low uptake by cells, intracellular 
DMAV is highly toxic by the production of ROS through the redox equilibrium between 
DMAV and DMAIII in the presence of GSH.  
 
73/85/ 
 73 
References 
 
(1) National Research Council (1999) Arsenic in Drinking Water. National 
Academy Press, Washington, D. C. 
(2) National Research Council (2001) Arsenic in Drinking Water 2001 Update. 
National Academy Press, Washington, D. C. 
(3) Yamauchi, H., and Yamamura, Y. (1979) Dynamic change of inorganic 
arsenic and methylarsenic compounds in human urine after oral intake as 
arsenic trioxide. Ind. Health, 17, 79-83. 
(4) Vahter, M., and Marafante, E. (1983) Intracellular interaction and metabolic 
fate of arsenite and arsenate in mice and rabbits. Chem. Biol. Interact. 47, 
29-44. 
(5) Mandal, B. K., and Suzuki, K. T. (2002) Arsenic round the world: a review. 
Talanta 58, 201-235. 
(6) Nakamuro, K., and Sayato, Y. (1981) Comparative studies of chromosomal 
aberration induced by trivalent and pentavalent arsenic. Mutat. Res. 88, 
73–80. 
(7) Nesnow, S., Roop, B. C., Lambert, G., Kadiiska, M., Mason, R. P., Cullen, W. 
R., and Mass, M. J. (2002) DNA damage induced by methylated trivalent 
arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 15, 
1627-1634. 
(8) Wang, T. S., Chung, C. H., Wang, A. S., Bau, D. T., Samikkannu, T., Jan, K, 
Y., Cheng, Y. M., and Lee, T. C. (2002) Endonuclease III, 
formamidopyrimidine DNA glycosylase, and proteinase K additively 
enhance arsenic-induced DNA strand breaks in human cells. Chem. Res. 
Toxicol. 15, 1254–1258. 
(9) Kligerman, A. D., Doerr, C. L., Tennant, A. H., Harrington-Brock, K., Allen, 
J. W., Winkfield, E., Poorman-Allen, P., Kundu, B., Funasaka, K., Roop, B. 
C., Mass, M. J., and DeMarini, D. M. (2003) Methylated trivalent arsenicals 
as candidate ultimate genotoxic forms of arsenic: induction of chromosomal 
mutations but not gene mutations. Environ. Mol. Mutagen 42, 192–205. 
(10) Schwerdtle, T., Walter, I., Mackiw, I., and Hartwig, A. (2003) Induction of 
oxidative DNA damage by arsenite and its trivalent and pentavalent 
methylated metabolites in cultured human cells and isolated DNA. 
Carcinogenesis 24, 967–974. 
(11) Lindgren, A., Vahter, M., and Dencker, L. (1982) Autoradiographic studies 
74/85/ 
 74 
on the distribution of arsenic in mice and hamsters administered 
74As-arsenite or arsenate. Acta Pharmacol. Toxicol. 51, 253-265. 
(12) Shi, H., Hudson, L. G., Ding, W., Wang, S., Cooper, K. L., Liu, S., Chen, Y., 
Shi, X., and Liu, K. J. (2004) Arsenite causes DNA damage in keratinocytes 
via generation of hydroxyl radicals. Chem. Res. Toxicol. 17, 871-878. 
(13) Hei, T. K., Liu, S. X., and Waldren, C. (1998) Mutagenicity of arsenic in 
mammalian cells: role of reactive oxygen species. Proc. Natl. Acad. Sci. 95, 
8103-8107. 
(14) Liu, F., and Jan, K. Y. (2000) DNA damage in arsenite and cadmium-treated 
bovine aortic endothelial cells. Free Radical Biol. Med. 28, 55-63. 
(15) Ding, W., Hudson, L. G., and Liu, K. J. (2005) Inorganic arsenic compounds 
cause oxidative damage to DNA and protein by inducing ROS and RNS 
generation in human keratinocytes. Mol. Cell Biochem. 279, 105-112. 
(16) Naranmandura, H., Suzuki, N., and Suzuki, K. T. (2006) Trivalent arsenicals 
are bound to proteins during reductive methylation. Chem. Res. Toxicol. 19, 
1010-1018. 
(17) Marafante, E., Vahter, M., and Envall, J. (1985) The role of the methylation 
in the detoxication of arsenate in the rabbit. Chem. Biol. Interact. 56, 
225-238. 
(18) Gebel, T. W. (2002) Arsenic methylation is a process of detoxification 
through accelerated excretion. Int. J. Hyg. Environ. Health 205, 505-508. 
(19) Wei, M., Wanibuchi, H., Yamamoto, S., Li, W., and Fukushima, S. (1999) 
Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. 
Carcinogenesis 20, 1873–1876. 
(20) Yoshida, K., Inoue, Y., Kuroda, K., Chen, H., Wanibuchi, H., Fukushima, S., 
and Endo, G. (1998) Urinary excretion of arsenic metabolites after long-term 
oral administration of various arsenic compounds to rats. J. Toxicol. Environ. 
Health Part A 54, 179-192. 
(21) Hansen, H. R., Raab, A., Jaspars, M., Milne, B. F., and Feldmann, J. (2004) 
Sulfur-containing arsenical mistaken for dimethylarsinous acid [DMA(III)] 
and identified as a natural metabolite in urine: major implications for studies 
on arsenic metabolism and toxicity. Chem. Res. Toxicol. 17, 1086– 1091. 
(22) Raml, R., Rumpler, A., Goessler, W., Vahter, M., Li, L., Ochi, T., and 
Francesconi, K. A. (2007) Thio-dimethylarsinate is a common metabolite in 
urine samples from arsenic-exposed women in Bangladesh. Toxicol. Appl. 
Pharmacol. In press.  
75/85/ 
 75 
(23) Suzuki, K. T., Katagiri, A., Sakuma, Y., Ogra, Y., and Ohmichi, M. (2004) 
Distributions and chemical forms of arsenic after intravenous administration 
of dimethylarsinic and monomethylarsonic acids to rats. Toxicol. Appl. 
Pharmacol. 198, 336-344. 
(24) Naranmandura, H., Suzuki, N., Iwata, K., Hirano, K., and Suzuki, K. T. 
(2007) Arsenic metabolism and thioarsenicals in hamsters and rats. Chem. 
Res. Toxicol. 20, 616-624. 
(25) Aposhian, H. V., Gurzau, E. S., Le, X. C., Gurzau, A., Healy, S. M., Lu, X., 
Ma, M., Yip, L., Zakharyan, R. A., Maiorino, R. M., Dart, R. C., Tircus, M. 
G., Gonzalez-Ramirez, D., Morgan, D. L., Avram, D., and Aposhian, M. M. 
(2000) Occurrence of monomethylarsonous acid in urine of humans exposed 
to inorganic arsenic. Chem. Res. Toxicol. 13, 693-697. 
(26) Mandal, B. K., Ogra, Y., and Suzuki, K. T. (2001) Identification of 
dimethylarsinous and monomethylarsonous acids in human urine of the 
arsenic affected areas in West Bengal, India. Chem. Res. Toxicol. 14, 
371–378. 
(27) Okina, M., Yoshida, K., Kuroda, K., Wanibuchi, H., Fukushima, S., and 
Endo, G. (2004) Determination of trivalent methylated arsenicals in rat urine 
by liquid chromatography-inductively coupled plasma mass spectrometry 
after solvent extraction. J. Chromatogr. B 799, 209-215. 
(28) Wang, Z., Zhou, J., Lu, X., Gong, Z., and Le, X. C. (2004) Arsenic 
speciation in urine from acute promyelocytic leukemia patients undergoing 
arsenic trioxide treatment. Chem. Res. Toxicol. 17, 95-103. 
(29) Valenzuela, O. L., Borja-Aburto, V. H., Garcia-Vargas, G. G., 
Cruz-Gonzalez, M. B., Garcia-Montalvo, E. A., Calderon-Aranda, E. S., and 
Del Razo, L. M. (2005) Urinary trivalent methylated arsenic species in a 
population chronically exposed to inorganic arsenic. Environ. Health 
Perspect. 113, 250-254. 
(30) Suzuki, K. T., Iwata, K., Naranmandura, H., and Suzuki, N. (2007) 
Metabolic differences between two dimethylthioarsenicals in rats. Toxicol. 
Appl. Pharmacol. 218, 166-173. 
(31) Kuroda, K., Yoshida, K., Yoshimura, M., Endo, Y., Wanibuchi, H., 
Fukushima, S., and Endo, G. (2003) Microbial metabolite of dimethylarsinic 
acid is highly toxic and genotoxic. Toxicol. Appl. Pharmacol. 198, 345-353. 
(32) Suzuki, K. T., Mandal, B. K., Katagiri, A., Sakuma, Y., Kawakami, A., Ogra, 
Y., Yamaguchi, K., Sei, Y., Yamanaka, K., Anzai, M., Ohmichi, H., 
76/85/ 
 76 
Takayama, H., and Aimi, N. (2004) Dimethylthioarsenicals as arsenic 
metabolites and their chemical preparation. Chem. Res. Toxicol. 17, 914-921. 
(33) Kitchin, K. T. (2001) Recent advances in arsenic carcinogenesis: modes of 
action, animal model systems, and methylated arsenic metabolites. Toxicol. 
Appl. Pharmacol. 172, 249-261. 
(34) Yamanaka, K., Kato, K., Mizoi, M., An, Y., Takabayashi, F., Nakano, M., 
Hoshino, M., and Okada, S. (2004) The role of active arsenic species 
produced by metabolic reduction of dimethylarsinic acid in genotoxicity and 
tumorigenesis. Toxicol. Appl. Pharmacol. 198, 385-393. 
(35) Hughes, M. F., Kenyon, E. M., Edwards, B. C., Mitchell, C. T., Del Razo, L. 
M., and Thomas, D. J. (2003) Accumulation and metabolism of arsenic in 
mice after repeated oral administration of arsenate. Toxicol. Appl. Pharmacol. 
191, 202-210. 
(36) Hernandez-Zavala, A., Cordova, E., Del Razo, L. M., Cebrian, M. E., and 
Garrido, E. (2005) Effects of arsenite on cell cycle progression in a human 
bladder cancer cell line. Toxicology 207, 49-57. 
(37) Hirano, S., Cui, X., Li, S., Kanno, S., Kobayashi, Y., Hayakawa, T., and 
Shraim, A. (2003) Difference in uptake and toxicity of trivalent and 
pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch. 
Toxicol. 77, 305-312. 
(38) Dopp, E., Hartmann, L. M., Florea, A. M., Von Recklinghausen, U., Pieper, 
R., Shokouhi, B., Rettenmeier, A. W., Hirner, A. V., and Obe, G. (2004) 
Uptake of inorganic and organic derivatives of arsenic associated with 
induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) 
cells. Toxicol. Appl. Pharmacol. 201, 156-165. 
(39) Thomas, D. J., Styblo, M., and Lin, S. (2001) The cellular metabolism and 
systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176, 127–144. 
 
77/85/ 
 77 
 
 
 
 
Figure 1. Effect of DMMTAV in comparison with other arsenicals on the viability 
of A431 cells. 
Cells were exposed to various concentrations of iAsV (A), iAsIII (B), DMAV (C), DMAIII 
(D), and DMMTAV (E) for 24 h. The LC50 values for iAsV, iAsIII, DMAV, DMAIII and 
DMMTAV were calculated to be 571, 5.49, 843, 2.16 and 10.7 µM, respectively. Data 
are expressed as mean values±standard deviation (n=4).  
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Figure 2. Effect of DMMTAV on cell cycle arrest of A431 cells. 
Cells were exposed to iAsIII (5 µM), DMAIII (2 µM), and DMMTAV (10 µM) at the 
respective LC50 values for 24 h, and the cell cycle was examined using PI fluorescence 
by flow cytometry. Asterisks (*), significantly different from the control (incubation 
with medium alone) at *P<0.05 (n=3, mean±SD). 
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Figure 3. Effect of DMMTAV on cellular ROS production in A431 cells. 
Cells were exposed to iAsIII (5 µM), DMAIII (2 µM), and DMMTAV (10 µM) at the 
respective LC50 values for 24 h at 37° C, and the generation of ROS was estimated 
using HPF fluorescence by flow cytometry. Asterisks (*), significantly different from 
the control (incubation with medium alone) at *P<0.05 (n=3, mean±SD). 
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Figure 4. Concentrations of arsenic in the soluble and sediment (non-soluble) 
fractions of A431 cells after treatment with DMMTAV in comparison with other 
arsenicals. 
Cells were exposed to iAsIII (5 µM), DMAIII (2 µM), and DMMTAV (10 µM) at the 
respective LC50 values, for 24 h. The cells were disrupted with an ultrasonic generator, 
and then centrifuged at 105,000 g for 1 h at 4° C to obtain soluble (supernatant) and 
sediment fractions. The concentrations of arsenic in the soluble and sediment fractions 
were determined by ICP MS after ashing with HNO3 and H2O2. 
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Figure 5. Distributions of arsenic in the soluble fraction of A431 cells after 
exposure to DMMTAV in comparison with other arsenicals. 
Cells were exposed to iAsIII (5 µM), DMAIII (2 µM), and DMMTAV (10 µM) at the 
respective LC50 values, for 24 h. The cells were disrupted with an ultrasonic generator, 
and then centrifuged at 105,000 g for 1 h at 4 °C to obtain a soluble fraction 
(supernatant). The distribution of arsenic in the soluble fraction was determined by 
HPLC-ICP MS on a GS 220 HQ column. 
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Figure 6. Proposed mechanism underlying the production of ROS by the uptake of 
thioarsenical DMMTAV. 
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